US20210401916A1 - Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract - Google Patents
Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract Download PDFInfo
- Publication number
- US20210401916A1 US20210401916A1 US17/479,990 US202117479990A US2021401916A1 US 20210401916 A1 US20210401916 A1 US 20210401916A1 US 202117479990 A US202117479990 A US 202117479990A US 2021401916 A1 US2021401916 A1 US 2021401916A1
- Authority
- US
- United States
- Prior art keywords
- chrysanthemum
- muscle
- extract
- dicaffeoylquinic acid
- chrysanthemum extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007516 Chrysanthemum Nutrition 0.000 title claims abstract description 207
- 239000000284 extract Substances 0.000 title claims abstract description 111
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 title claims abstract description 98
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 244000189548 Chrysanthemum x morifolium Species 0.000 title claims description 199
- 208000021642 Muscular disease Diseases 0.000 title abstract description 37
- 230000004220 muscle function Effects 0.000 title abstract description 28
- 230000006872 improvement Effects 0.000 title abstract description 6
- 230000002265 prevention Effects 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 47
- 230000014509 gene expression Effects 0.000 claims abstract description 45
- 210000003205 muscle Anatomy 0.000 claims abstract description 34
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 claims abstract description 22
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 claims abstract description 22
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 claims abstract description 15
- 108010041191 Sirtuin 1 Proteins 0.000 claims abstract description 15
- 241000723353 Chrysanthemum Species 0.000 claims abstract 18
- 238000000034 method Methods 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 26
- 108010015181 PPAR delta Proteins 0.000 claims description 23
- 210000000663 muscle cell Anatomy 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 10
- 210000003470 mitochondria Anatomy 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- 210000001087 myotubule Anatomy 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000007102 metabolic function Effects 0.000 claims description 4
- 206010024264 Lethargy Diseases 0.000 claims description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 38
- 208000029578 Muscle disease Diseases 0.000 abstract description 36
- 239000002537 cosmetic Substances 0.000 abstract description 27
- 235000013305 food Nutrition 0.000 abstract description 22
- 102000008934 Muscle Proteins Human genes 0.000 abstract description 20
- 108010074084 Muscle Proteins Proteins 0.000 abstract description 20
- 230000002708 enhancing effect Effects 0.000 abstract description 19
- 108020004999 messenger RNA Proteins 0.000 abstract description 16
- 239000000090 biomarker Substances 0.000 abstract description 15
- 230000004069 differentiation Effects 0.000 abstract description 15
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 abstract description 13
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 abstract description 13
- 102100040669 F-box only protein 32 Human genes 0.000 abstract description 13
- 101710191029 F-box only protein 32 Proteins 0.000 abstract description 13
- 230000017854 proteolysis Effects 0.000 abstract description 13
- 108010056785 Myogenin Proteins 0.000 abstract description 9
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 abstract description 9
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract description 6
- 230000014616 translation Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000005445 natural material Substances 0.000 abstract description 3
- 102000004364 Myogenin Human genes 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 description 50
- 238000002360 preparation method Methods 0.000 description 48
- 230000001965 increasing effect Effects 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 28
- 239000000306 component Substances 0.000 description 27
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 230000036541 health Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 14
- 230000008437 mitochondrial biogenesis Effects 0.000 description 13
- 206010028289 Muscle atrophy Diseases 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000003086 colorant Substances 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 201000000585 muscular atrophy Diseases 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 230000002335 preservative effect Effects 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 102100032970 Myogenin Human genes 0.000 description 8
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 241000208838 Asteraceae Species 0.000 description 7
- KRZBCHWVBQOTNZ-FCXRPNKRSA-N O=C(/C=C/C1=CC=C(O)C(O)=C1)OC1CC(O)(C(=O)O)CC(OC(=O)/C=C/C2=CC(O)=C(O)C=C2)C1O Chemical compound O=C(/C=C/C1=CC=C(O)C(O)=C1)OC1CC(O)(C(=O)O)CC(OC(=O)/C=C/C2=CC(O)=C(O)C=C2)C1O KRZBCHWVBQOTNZ-FCXRPNKRSA-N 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HKNKLQZERRWNPL-XVYDYJIPSA-N CC1=CC=C(/C=C/C(=O)OC2CC(O)(C(=O)O)CC(OC(=O)/C=C/C3=CC(O)=C(O)C=C3)C2O)C=C1O Chemical compound CC1=CC=C(/C=C/C(=O)OC2CC(O)(C(=O)O)CC(OC(=O)/C=C/C3=CC(O)=C(O)C=C3)C2O)C=C1O HKNKLQZERRWNPL-XVYDYJIPSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- -1 glucose or fructose Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KRZBCHWVBQOTNZ-RDJMKVHDSA-N (3r,5r)-3,5-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101150057615 Syn gene Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000002035 hexane extract Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 102000000132 Alpha tubulin Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 description 1
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- XLOPRKKSAJMMEW-UHFFFAOYSA-N chrysanthemic acid Chemical compound CC(C)=CC1C(C(O)=O)C1(C)C XLOPRKKSAJMMEW-UHFFFAOYSA-N 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 101150046266 foxo gene Proteins 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000006545 glycolytic metabolism Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000015074 other food component Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- VLCLHFYFMCKBRP-UHFFFAOYSA-N tricalcium;diborate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]B([O-])[O-].[O-]B([O-])[O-] VLCLHFYFMCKBRP-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Definitions
- the present invention relates to a composition for preventing, improving or treating a muscle disorder or improving muscle function, and more particularly, to a composition for preventing, improving or treating a muscle disorder or improving muscle function, which includes 3,5-dicaffeoylquinic acid or a Chrysanthemum extract.
- Skeletal muscle fibers are generally classified as type 1 (oxidative/slow) and type 2 (glycolytic/fast) fibers, and muscle fibers exhibit significant differences in shrinkage, metabolism and susceptibility to fatigue.
- the type 1 fiber has a large number of mitochondria and mainly uses an oxidative metabolism for energy generation, and therefore stably provides ATP for a long time to withstand fatigue. Therefore, muscle wasting does not occur in the skeletal muscles with a lot of type 1 fibers (Muscle Nerve, 31: 339-348, 2005).
- Type 2 fibers have low contents of mitochondria and oxidases and are dependent on a glycolytic metabolism as a main energy source such that the fibers become easily tired.
- Peroxisome Proliferator Activated Receptor ⁇ is a main transcription regulatory factor which is highly present in a skeletal muscle, particularly, type 1 fiber (10 fold of PPAR ⁇ , and 50 fold of PPAR ⁇ ), activates enzymes involved in ⁇ -oxidation of a long-chain fatty acid to burn fats in adipose cells (Cell, 113: 159-170, 2003), and is the first transcription factor which promotes type 1 fibrosis.
- Such PPAR ⁇ is known to be involved in a complicated pathway for regulating mitochondrial biogenesis upon activation and promoting exercise performance and resistance to obesity (PLoS Biol., 2: 1532-1539, 2004). Therefore, type 1 fibers generated adaptively through exercise are known to be resistant to fatigue.
- Muscle atrophy occurs by a gradual decrease in muscle mass, and refers to muscular weakness and degeneration (Cell, 119(7): 907-910, 2004). Muscle atrophy is promoted by inactivity, oxidative stress or chronic inflammation, and weakens muscle function and exercise performance (Clin. Nutr., 26(5): 524-534, 2007). The most important factor determining muscle function is muscle mass, which is maintained by a balance of protein synthesis and degradation. Muscle atrophy occurs when protein degradation happens more than protein synthesis (Int. J. Biochem. Cell Biol., 37(10): 1985-1996, 2005).
- Chrysanthemum morifolium Ramat. which is generally used for ornamental plants, for making Chrysanthemum tea using flower thereof, and for a salad, soup or alcohol (Edible Medicinal and Non-Medicinal Plants, 7: 250-269, 2012). It has been reported that Chrysanthemum has an antioxidative effect (Afr. J. Biotechnol., 10(82): 19197-19202, 2011), an anti-tuberculosis action (Biol. Pharm. Bull., 28(1):158-160, 2005), and an anticancer effect (Cancer Lett., 177: 7-12, 2002).
- the present invention is directed to providing a pharmaceutical composition for preventing or treating a muscle disorder, which includes a Chrysanthemum extract as an active ingredient.
- the present invention is also directed to providing a pharmaceutical composition for preventing or treating a muscle disorder, which includes 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient:
- the present invention is also directed to providing a food composition for preventing or improving a muscle disorder, or improving muscle function, which contains a Chrysanthemum extract as an active ingredient.
- the present invention is also directed to providing a food composition for preventing or improving a muscle disorder, or improving muscle function, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- the present invention is also directed to providing a cosmetic composition for preventing or improving a muscle disorder, or improving muscle function, which contains a Chrysanthemum extract as an active ingredient.
- the present invention is also directed to providing a cosmetic composition for preventing or improving a muscle disorder, or improving muscle function, which contains a compound of Formula 1 as an active ingredient.
- the present invention is also directed to providing a pharmaceutical composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- the present invention is also directed to providing a pharmaceutical composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient:
- the present invention is also directed to providing a food composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- the present invention is also directed to providing a food composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- the present invention is also directed to providing a cosmetic composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- the present invention is also directed to providing a cosmetic composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating a muscle disorder, which contains a Chrysanthemum extract as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating a muscle disorder, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
- the present invention provides a food composition for preventing or improving a muscle disorder or improving muscle function, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a cosmetic composition for preventing or improving a muscle disorder or improving muscle function, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the Chrysanthemum extract may include 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- the Chrysanthemum extract may be obtained by extracting Chrysanthemum using water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent.
- the Chrysanthemum extract may be obtained by extracting Chrysanthemum through subcritical fluid extraction, supercritical fluid extraction, or high-pressure extraction.
- the 3,5-dicaffeoylquinic acid a compound isolated from the Chrysanthemum extract, or a synthetic compound or a commercially available compound may be used.
- the muscle disorder may be a muscle disorder caused by a decrease in muscle function, muscle wasting or muscle degeneration.
- the muscle disorder may be one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia, cachexia and sarcopenia.
- the composition may promote formation of muscle fibers.
- the present invention provides a pharmaceutical composition for enhancing exercise performance, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a food composition for enhancing exercise performance, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention provides a cosmetic composition for enhancing exercise performance, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- the composition may have effects of increasing exercise endurance, reinforcing muscle strength, enhancing balance, and/or enhancing exercise adaptation.
- the composition may increase the oxidative metabolic function of mitochondria.
- the composition may promote formation of muscle fibers.
- the present invention relates to a composition for preventing and treating a muscle disorder containing a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as active ingredients, wherein the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function.
- the Chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of PPAR ⁇ and PGC-1 ⁇ , which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.
- FIG. 1 shows a result of measuring the activity of a PPAR ⁇ ligand-binding domain according to treatment with a Chrysanthemum optimized hot water extract and 10%, 30%, 50%, 70% and 90% ethanol extracts.
- FIG. 2 shows a result of measuring expression levels of PGC-1 ⁇ according to treatment with a Chrysanthemum optimized hot water extract and 10%, 30%, 50%, 70% and 90% ethanol extracts.
- FIG. 3 shows a result of measuring the activity of a PPAR ⁇ ligand binding domain according to treatment with a 95% ethanol extract of Chrysanthemum.
- FIG. 4 shows a result of measuring an expression level of SIRT1 according to treatment with a 95% ethanol extract of Chrysanthemum.
- FIG. 5 shows a result of measuring an expression level of PGC-1 ⁇ according to treatment with a 95% ethanol extract of Chrysanthemum.
- FIG. 6 shows a result of measuring an amount of mitochondrial biogenesis according to treatment with a 30% ethanol extract of Chrysanthemum.
- FIG. 7 shows a result of measuring mRNA expression levels of atrogin-1 and MuRF-1 according to treatment with a 30% ethanol extract of Chrysanthemum.
- FIG. 8 shows a result of measuring protein expression levels of mTOR, p70S6K and 4EBP1 according to treatment with a 30% ethanol extract of Chrysanthemum.
- FIG. 9 shows a result of measuring mRNA expression levels of MyoD and myogenin according to treatment with a 30% ethanol extract of Chrysanthemum.
- FIG. 10 shows a result of measuring an expression level of SIRT1 according to treatment with 3,5-dicaffeoylquinic acid.
- FIG. 11 shows a result of measuring an expression level of PGC-1 ⁇ according to treatment with 3,5-dicaffeoylquinic acid.
- FIG. 12 shows a result of measuring mRNA expression levels of atrogin-1 and MuRF-1 according to treatment with 3,5-dicaffeoylquinic acid.
- FIG. 13 shows a result of measuring an mTOR protein expression level according to treatment with 3,5-dicaffeoylquinic acid.
- FIG. 14 shows a result of measuring mRNA expression levels of MyoD and myogenin according to treatment with 3,5-dicaffeoylquinic acid.
- the inventors had discovered that a Chrysanthemum extract and 3,5-dicaffeoylquinic acid have an activity of forming muscle and an activity of enhancing exercise performance, and therefore the present invention was completed.
- muscle used herein encompasses to a tendon, a muscle and a cord
- muscle function used herein refers to an ability of generating power by muscle contraction, and includes muscular strength, which is the ability of muscles to exert maximum contraction to overcome resistance, muscle endurance, which is the ability of muscles to show how long or how many contractions and relaxations are repeated with a given weight, and agility, which is the ability of exerting strong power within short time.
- muscular strength which is the ability of muscles to exert maximum contraction to overcome resistance
- muscle endurance which is the ability of muscles to show how long or how many contractions and relaxations are repeated with a given weight
- agility which is the ability of exerting strong power within short time.
- Such muscle functions are governed by the liver and proportional to muscle mass, and the “improvement in muscle function” refers to more enhancement in muscle function.
- exercise performance refers to a degree of rapidly, intensively, accurately, longer and smoothly performing an action when body actions shown in normal life or sports are explicitly divided into running, hopping, throwing and swimming, and is defined by parameters such as muscular strength, agility and endurance, and the “enhancement in exercise performance” refers to improvement or enhancement in exercise performance.
- the present invention provides a pharmaceutical composition for preventing or treating a muscle disorder containing a Chrysanthemum extract as an active ingredient.
- the Chrysanthemum extract may include 3,5-dicaffeoylquinic acid of Formula 1 below as an active ingredient.
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, but the present invention is not limited thereto.
- the leaves, stems, flowers, root, skin or fruit of the Chrysanthemum, or a mixture thereof may be subjected to extraction.
- the Chrysanthemum extract may be extracted using water, an organic solvent having 1 to 4 carbon atoms or a mixture thereof as a solvent.
- the organic solvent may be one or more selected from the group consisting of a C1 to C4 lower alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane and petroleum ether, but the present invention is not limited.
- the lower alcohol used in extraction of the Chrysanthemum is more preferably ethanol or methanol, and most preferably ethanol.
- ethanol as a solvent for extraction of the Chrysanthemum
- an effect of enhancing exercise performance and an activity to inhibit muscular protein degradation may be more significantly exhibited in preparation of a Chrysanthemum extract.
- a 30 to 95% ethanol aqueous solution is preferably used as a solvent, but the present invention is not limited thereto.
- dry Chrysanthemum may be ground, and then water, an alcohol or a mixture thereof is preferably added 2 to 20 fold, and more preferably, added 3 to 10 fold, the weight of the ground Chrysanthemum, but the present invention is not limited thereto.
- An extraction temperature is preferably 20 to 100° C., and more preferably 60 to 100° C., but the present invention is not limited thereto.
- the extraction time is preferably 1 to 10 hours, and more preferably 2 to 5 hours, but the present invention is not limited thereto.
- An extraction method can be any one of cold extraction, ultrasonic extraction and reflux cooling extraction, and the reflux cooling extraction is preferably used, but the present invention is not limited thereto.
- the number of extraction cycles is preferably 1 to 5 times, and more preferably 2 or 3 times, but the present invention is not limited thereto.
- Chrysanthemum extract may be attained by ultra-high pressure extraction, subcritical fluid extraction or supercritical fluid extraction.
- the present invention may also provide a pharmaceutical composition for preventing or treating a muscle disorder, which contains a compound of Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient:
- the compound of Formula 1 is called 3,5-dicaffeoylquinic acid.
- the structural name of the 3,5-dicaffeoylquinic acid is (3R,5R)-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid, and corresponds to CAS No. 89919-62-0.
- a compound isolated or synthesized from a Chrysanthemum extract or may be a commercially-available compound may be used.
- the composition according to the present invention may inhibit muscle loss. Specifically, as mRNA expression of atrogin-1 and MuRF1, which are the main biomarkers involved in muscle protein degradation, may be decreased, and mRNA expression of the mTOR protein, which is the main biomarker involved in formation of a muscle protein and myogenin and MyoD, which are biomarkers related to muscle differentiation, may be increased, the composition may be used in prevention or treatment of a muscle disorder.
- the muscle disorder of the present invention may be a muscle disorder caused by a decrease in muscle function, muscle wasting or muscle degeneration, which is a disease which has been reported in the art, and specifically, any one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia and sarcopenia, but the present invention is not limited thereto.
- the muscle wasting or degeneration is caused by an innate factor, an acquired factor, aging or the like, and the muscle wasting contributes to gradual loss of muscle mass, and weakening and degeneration of a muscle, particularly, a skeletal muscle, a voluntary muscle or a heart muscle.
- a content of the Chrysanthemum extract may be 1 to 100 ⁇ g/mL, and a content of the 3,5-dicaffeoylquinic acid may be 1 to 100 ⁇ M, but the present invention is not limited thereto.
- the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be formulated in oral preparations such as a powder, a granule, a capsule, a suspension, an emulsion, a syrup and an aerosol, a preparation for external use, a suppository and a sterilized injection according to a conventional method, and may include a suitable carrier, excipient or diluent, which is conventionally used in preparation of a pharmaceutical composition for formulation.
- excipient or diluent various compounds including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, or a mixture thereof may be used.
- the pharmaceutical composition may be prepared with a diluent or excipient such as a filler, a thickening agent, a binder, a wetting agent, a disintegrant or a surfactant, which is generally used in the preparation.
- a diluent or excipient such as a filler, a thickening agent, a binder, a wetting agent, a disintegrant or a surfactant, which is generally used in the preparation.
- a solid preparation for oral administration may be prepared by mixing at least one or more excipients such as starch, calcium borate, sucrose, lactose, and gelatin with the Chrysanthemum extract.
- excipients such as starch, calcium borate, sucrose, lactose, and gelatin
- lubricants such as magnesium stearate, talc, etc. may also be used.
- a liquid preparation for oral administration may be a suspension, a liquid for internal use, an emulsion, or a syrup, and may include various excipients, for example, a wetting agent, a sweetening agent, a flavoring agent, a preservative, etc., other than a simple diluent frequently used, for example, water or liquid paraffin.
- preparations for non-oral administration may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilizing agent and a suppository.
- a non-aqueous solvent or suspension propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, or an injectable ester such as ethyl oleate may be used.
- a suppository base Witepsol, Tween 61, cacao butter, laurin fat, or glycerogelatin may be used.
- a preferable dose of the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be determined by a patient's condition and body weight, severity of a disease, a drug type, an administration route and a duration, and may be suitably selected by those of ordinary skill in the art.
- the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be administered daily at 0.0001 to 2,000 mg/kg, and preferably 0.001 to 2,000 mg/kg.
- the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be administered once or in divided doses per day. However, the scope of the present invention is not limited by the dose.
- the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be administered to mammals such as rats, mice, livestock and humans via various routes.
- the administration may be performed orally, intravenously, intramuscularly, subcutaneously, intrathecally, or intracerebroventricularly.
- the present invention provides a health functional food composition for preventing or improving a muscle disorder, which contains a Chrysanthemum extract as an active ingredient.
- the present invention provides a health functional food composition for preventing or improving a muscle disorder, which contains a compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- the 3,5-dicaffeoylquinic acid of Formula 1 a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above.
- the present invention provides a health functional food composition for preventing or improving a muscle disorder, which contains a Chrysanthemum extract as an active ingredient.
- the present invention also provides a food composition for preventing a muscle disorder or improving muscle function, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- 3,5-dicaffeoylquinic acid of Formula 1 a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above.
- the Chrysanthemum extract or 3,5-dicaffeoylquinic acid when used as an additive for health functional food, it may be added alone or in combination with other food or food components, and may be suitably used according to a conventional method.
- a mixing amount of the active ingredient may be suitably determined according to a purpose of use, for example, for prevention, health care or treatment.
- a health functional food can be produced in the form of common food or beverage, as well as a powder, a granule, a pill, a tablet or a capsule.
- examples of food to which the material can be added may include meat, sausage, bread, chocolate, candy, snacks, confectionaries, pizza, ramen, other noodles, gums, dairy products including ice cream, soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, and may include all types of food in a conventional meaning.
- the Chrysanthemum extract or 3,5-dicaffeoylquinic acid may be added at 15 parts by weight or less, and preferably, 10 parts by weight or less with respect to 100 parts by weight of the raw materials.
- the amount may be in the range or less, and since the present invention uses a fraction obtained from a natural substance and thus there is no problem in stability, the food may be used in an amount higher than the above range.
- a beverage among the health functional food according to the present invention may contain various flavoring agents or a natural carbohydrate as an additional component like a conventional beverage.
- the above-described natural carbohydrate may be a monosaccharide such as glucose or fructose, a disaccharide such as maltose or sucrose, a polysaccharide such as dextrin or cyclodextrin, or a sugar alcohol such as xylitol, sorbitol or erythritol.
- a sweetening agent a natural sweetening agent such as thaumatin or a stevia extract, or a synthetic sweetening agent such as saccharine or aspartame may be used.
- a ratio of the natural carbohydrate may be approximately 0.01 to 0.04 g, and preferably, approximately 0.02 to 0.03 g, per 100 mL of the beverage according to the present invention.
- the health functional food for improving muscle function may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, a protective colloid thickening agent, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, and a carbonating agent used in carbonated drinks.
- the composition for improving muscle function may contain flesh for producing natural fruit juice, fruit drinks and vegetable drinks. Such components may be used alone or in combination.
- a ratio of the additive is not limited, but is generally selected in a range of 0.01 to 0.1 part by weight with respect to 100 parts by weight of the health functional food of the present invention.
- the present invention provides a cosmetic composition for improving muscle function, which contains a Chrysanthemum extract as an active ingredient.
- the present invention provides a cosmetic composition for improving muscle function, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- 3,5-dicaffeoylquinic acid of Formula 1 a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above.
- the cosmetic composition of the present invention may contain a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and also include a dermatologically acceptable excipient, and thus can be prepared in the form of a composition for basic cosmetics (toner, essence, cleanser such as cleansing foam or cleansing water, pack, and body oil), a composition for color cosmetics (foundation, lipstick, mascara, and makeup base), a composition for hair products (shampoo, rinse, hair conditioner, and hair gel) and soap.
- a composition for basic cosmetics toner, essence, cleanser such as cleansing foam or cleansing water, pack, and body oil
- color cosmetics foundation, lipstick, mascara, and makeup base
- hair products shampoo, rinse, hair conditioner, and hair gel
- an emollient As the excipient, an emollient, a skin permeation enhancer, a colorant, fragrance, an emulsifier, a thickener or a solvent may be included, but the present invention is not limited thereto.
- a flavor, a colorant, an antibacterial agent, an antioxidant, a preservative and a moisturizer may be further included, and for improvement in physical properties, a thickening agent, inorganic salts, and synthetic polymer materials may be included.
- a cleanser or soap when a cleanser or soap are prepared using the cosmetic composition of the present invention, it may be easily prepared by adding the Chrysanthemum extract or 3,5-dicaffeoylquinic acid to a conventional cleanser or soap base.
- a cream may be prepared by adding the Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a salt thereof to a common oil-in-water (OW) cream base.
- OW oil-in-water
- a synthetic or natural substance such as a protein, a mineral or a vitamin may be further added to improve physical properties.
- a content of the Chrysanthemum extract or 3,5-dicaffeoylquinic acid contained in the cosmetic composition of the present invention is, but is not limited to, preferably 0.001 to 10 wt %, and more preferably 0.01 to 5 wt %, with respect to the total weight of the composition. When the content is less than 0.001 wt %, a desired antiaging or wrinkle-improving effect may not be expected, and when the content is more than 10 wt %, there may be difficulty in stability or formulation.
- the present invention provides a pharmaceutical composition for improving exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- the present invention also provides a pharmaceutical composition for improving exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof.
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- 3,5-dicaffeoylquinic acid of Formula 1 a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above.
- the composition may increase the oxidative metabolic function of mitochondria, and specifically, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid of the present invention may improve exercise performance by significantly increasing SIRT1 and PGC-1 ⁇ expression levels in muscle cells.
- composition may promote formation of muscle fibers, and specifically, the Chrysanthemum extract of the present invention may improve exercise performance by significantly increasing PPAR ⁇ activity.
- composition may prevent or treat any one or more diseases selected from the group consisting of a degenerative disease, mitochondrial dysfunction, a decrease in endurance, a decrease in agility, lethargy, muscle disuse and depression as the enhancement in exercise performance is induced.
- diseases selected from the group consisting of a degenerative disease, mitochondrial dysfunction, a decrease in endurance, a decrease in agility, lethargy, muscle disuse and depression as the enhancement in exercise performance is induced.
- the present invention provides a food composition for improving exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- the present invention provides a food composition for improving exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- the 3,5-dicaffeoylquinic acid of Formula 1 a compound isolated or synthesized from the Chrysanthemum extract or a commercially available compound may be used, and the 3,5-dicaffeoylquinic acid may be the same as described above.
- the present invention provides a cosmetic composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- the present invention provides a cosmetic composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- 3,5-dicaffeoylquinic acid of Formula 1 a compound isolated or synthesized from the Chrysanthemum extract or a commercially available compound may be used, and details are the same as described above.
- Dry Chrysanthemum was ground with a mixer, 10 g of the ground Chrysanthemum sample was added to 100 mL of methanol, and was extracted while stirring at 28° C. for 180 minutes.
- the extracted sample was filtrated under reduced pressure using a Whatman No. 2 filter, and the resulting filtrate was concentrated using a vacuum rotary concentrator to remove a solvent component, thereby preparing a methanol extract of Chrysanthemum.
- a process was performed by the same method as described in Example 1-(1), except that 10%, 30%, 50%, 70%, 90% or 95% ethanol was used, and as a result, a 10%, 30%, 50%, 70%, 90% or 95% ethanol extract of Chrysanthemum was prepared.
- a process was performed by the same method as described in Example 1-(1), except that ethyl acetate was used, and as a result, an ethyl acetate extract of Chrysanthemum was prepared.
- a process was performed by the same method as described in Example 1-(1), except that hexane was used, and as a result, a hexane extract of Chrysanthemum was prepared.
- Dry Chrysanthemum was ground with a mixer, 10 g of the ground Chrysanthemum sample was added to 100 mL of water, and was extracted while stirring at 82° C. for 180 minutes. Afterward, a process was performed by the same method as described in Example 1-(1), and as a result, a hot water extract of Chrysanthemum was prepared.
- Dry Chrysanthemum was ground with a mixer, and 1 g of the ground Chrysanthemum sample and 76 mL of 18% ethanol were put into a polyethylene pack, and extracted using an ultra-high pressure extractor (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan). Conditions for ultra-high pressure extraction included an extraction pressure of 320 MPa and an extraction time of 5 minutes. The extracted sample was filtered with a Whatman No. 2 filter, the resulting filtrate was concentrated using a vacuum rotary concentrator to remove a solvent component, thereby preparing an ultra-high pressure extract of Chrysanthemum.
- an ultra-high pressure extractor Fescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan
- Dry Chrysanthemum was ground with a mixer, 1 g of the ground Chrysanthemum sample was charged into a sample cartridge, and extracted using a supercritical fluid extractor (SFX 3560, Isco Inc., Lincoln, Nebr., USA).
- Conditions for supercritical fluid extraction included an extraction pressure of 20 MPa, an extraction temperature of 60° C., a supercritical CO 2 flow rate of 60 mL/min, and an extraction time of 60 minutes.
- a pressure of the extractor was reduced to terminate a supercritical fluid state, thereby obtaining a Chrysanthemum supercritical fluid extract.
- Dry Chrysanthemum was ground with a mixer, 50 g of the ground Chrysanthemum and 1 L of water were put into a subcritical water reactor in a subcritical extractor (Biovan, Gyeonggi, Korea) and then sealed. After sealing, a temperature of the reactor was increased up to 200° C., and when the temperature of the reactor reached 200° C., the temperature was maintained for 20 minutes for extraction. After 20 minutes, the extract was transferred to a storage tank to which cold water was provided to be rapidly cooled down to 30° C., and to isolate a suspended residue, only a supernatant was subjected to centrifugation at 3,600 rpm for 30 minutes. A solvent was thoroughly removed using a freeze dryer (IlShin Lab Co. Ltd., Seoul, Korea), thereby obtaining a subcritical extract of Chrysanthemum.
- a subcritical extractor Biovan, Gyeonggi, Korea
- the ethanol extract of Chrysanthemum prepared in Example 1-(2) was dissolved in 2 L of water, and isolated in three different solvents using ethyl acetate and n-butanol.
- the n-butanol solvent portion was loaded in an RP-18-filled column, and fractionated with a solvent system which changes a methanol ratio from 15 to 70%. According to the fractionation sequence, 16 subfractions were obtained.
- the seventh fraction was concentrated again using a vacuum rotary concentrator to remove a solvent component.
- the concentrate was loaded in a RP-18-filled column, and then fractioned with methanol. According to the fractionation sequence, 6 subfractions were obtained.
- 3,5-dicaffeoylquinic acid which is the compound of the following Formula 1
- 3,5-dicaffeoylquinic acid which is the compound of the following Formula 1
- Dry Chrysanthemum was ground with a mixer, 10 g of the ground Chrysanthemum sample was added to 100 mL of 30% ethanol and extracted at 70° C. for 3 hours.
- the extracted sample was filtrated under low pressure with a Whatman No. 2 filter, the filtered extract solution was concentrated with a vacuum rotary concentrator to remove a solvent component, thereby preparing a 30% ethanol extract of Chrysanthemum, and here, a yield of the Chrysanthemum extract was 23.24%.
- a content of 3,5-dicaffeoylquinic acid, which is the compound of the following Formula 1, in the Chrysanthemum extract was analyzed by high-performance liquid chromatography (HPLC, YL9100 HPLC system; Younglin Instruments CO., Ltd., Gyeonggi, Korea).
- HPLC high-performance liquid chromatography
- 0.01% phosphoric acid and an acetonitrile solvent were used, and a 30% ethanol extract of Chrysanthemum was analyzed at a wavelength of 330 nm and a flow rate of 1.0 mL/min.
- the 3.5-dicaffeoylquinic acid was detected at a retention time of 11 minutes, and contained at 2.17% in the 30% ethanol extract of Chrysanthemum.
- COS7 cells (CV-1 in Origin Simian-7, ATCC, Manassas, Va., USA) which do not express a PPAR-related gene were cultured in Dulbecco Modified Eagle Medium (DMEM, Hyclone, Logan, Utah, USA) containing 10% fetal bovine serum (FBS, Gibco, Gaithersburg, Md., USA), and then cultured in a 24-well plate for 5 hours or longer.
- DMEM Dulbecco Modified Eagle Medium
- FBS Gibco, Gaithersburg, Md., USA
- a plus reagent (Aptabio, Gyeonggi, Korea), a PPAR ⁇ plasmid and a pFR-luciferase vector (Stratagene, La Jolla, Calif., USA) were mixed together with serum-free DMEM (Hyclone), incubated for 15 minutes, mixed with a Lipofecter reagent (Aptabio), incubated again at room temperature for 15 minutes, and then dropped on the cells. After 4 hours, the medium was replaced with a 10% FBS (Gibco)-containing DMEM (Hyclone), and stabilized for 24 hours.
- the hot water extract of Chrysanthemum, and the 10%, 30%, 50% and 70% ethanol extracts significantly increased PPAR ⁇ activity (*p ⁇ 0.05).
- the Chrysanthemum extract of the present invention is a ligand of PPAR ⁇ and has an excellent ability to activate PPAR ⁇ .
- COS7 cells (ATCC) were transfected with a pTA-Luc-PGC-1 ⁇ plasmid (Addgene) by the same method as described in Experimental Example 1-(1).
- a pTA-Luc-PGC-1 ⁇ plasmid (Addgene)
- the hot water extract of Chrysanthemum and 10%, 30%, 50% and 70% ethanol extracts significantly increased the activity of PGC-1 ⁇ , which is a main factor involved in mitochondrial biogenesis (*p ⁇ 0.05). This means that an ability of the Chrysanthemum extract of the present invention to promote mitochondrial biogenesis by activating PGC-1 ⁇ is excellent.
- the 95% ethanol extract of Chrysanthemum increased PPAR ⁇ activity in a concentration-dependent manner, and compared with a control group, exhibited a significant difference (**p ⁇ 0.01).
- the 95% ethanol extract of Chrysanthemum according to the present invention is a ligand of PPAR ⁇ and has an excellent ability to activate PPAR ⁇ .
- COS7 cells (ATCC) were transfected with a pTA-Luc-SIRT1 plasmid (Addgene) by the same method as described in Experimental Example 1-(1).
- the 95% ethanol extract of Chrysanthemum prepared in Example 1-(2) was treated at 20, 30 or 40 ⁇ g/mL, and the result is shown in FIG. 4 .
- the 95% ethanol extract of Chrysanthemum significantly increased an expression level of SIRT1, which is a main factor involved in mitochondrial biogenesis (**p ⁇ 0.01).
- SIRT1 a main factor involved in mitochondrial biogenesis
- Example 1-(2) To confirm an effect of increasing an expression level of PGC-1 ⁇ by treatment of COST cells (ATCC) with the 95% ethanol extract of Chrysanthemum, the 95% ethanol extract of Chrysanthemum, prepared in Example 1-(2), was treated at 10 or 40 ⁇ g/mL by the same method as described in Experimental Example 1-(2). The result is shown in FIG. 5 .
- L6 myoblasts (ATCC), which are muscle cells, were added at 1 ⁇ 10 5 cell/mL to a 6-well plate with 10% FBS (Gibco)-containing DMEM (Hyclone).
- FBS Gibco
- DMEM fetal bovine serum
- the cells were treated with the 30% ethanol extract of Chrysanthemum prepared in Example 1-(2), which was dissolved in 2% HS (Hyclone)-containing DMEM (Hyclone) at 5, 10 or 20 ⁇ g/mL, to induce myotube differentiation.
- the differentiation was performed for total of 6 days by replacing the medium and a sample with fresh ones every two days.
- the medium was suctioned, and 100 nM Mitotracker (Thermo Fisher Scientific Inc., Waltham, Mass., USA) dissolved in DMEM (Hyclone) was treated for 30 minutes.
- the medium was removed, 1 mL of a methanol solvent was added to each well, and fluorescence was measured at an absorption wavelength of 490 nm and an emission wavelength of 516 nm using a microplate reader (Versa Max, Sunnyvale, Calif., USA). The result is shown in FIG. 6 .
- the 30% ethanol extract of Chrysanthemum significantly increased an amount of mitochondria in a muscle (*p ⁇ 0.05, **p ⁇ 0.01). This means that the 30% ethanol extract of Chrysanthemum according to the present invention promotes mitochondrial biogenesis and has an excellent ability to increase exercise performance.
- L6 myoblasts (ATCC), which are muscle cells, were added at 1 ⁇ 10 5 cell/mL to a 6-well plate with 10% FBS (Gibco)-containing DMEM (Hyclone). When the cell density reached approximately 80 to 85%, the medium in the well was removed, the cells were treated with 2% HS (Hyclone)-containing DMEM (Hyclone) to induce myotube differentiation. The differentiation was performed for total of 6 days by replacing the medium and a sample with fresh ones every two days.
- DMEM Hyclone
- TNF- ⁇ tumor necrosis factor alpha
- PCM PeproTech, Rocky Hills, N.J., USA
- TRIzol reagent Takara, Shiga, Japan
- the isolated total RNA was quantified using a NanoDrop 1000 (Thermo Fisher Scientific Inc.).
- cDNA was synthesized from 16 ⁇ L of the quantified RNA using a Reverse Transcriptase Premix (ELPIS-Biotech, Daejeon, Korea) and a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, Calif., USA) under conditions of 42° C. for 55 minutes and 70° C. for 15 minutes. PCR was performed in 30 cycles using 4 ⁇ L out of 16 ⁇ L of the produced cDNA, specific primers (Bioneer, Daejeon, Korea) below and a PCR premix (ELPIS-Biotech) at 95° C. for 30 seconds, 60° C. for 1 minutes, and 72° C. for 1 minute.
- EPIS-Biotech Reverse Transcriptase Premix
- the sequences of the primers used in the PCR are shown in Table 1 below.
- the cDNA amplified by PCR was isolated by electrophoresis using a 1.5% agarose gel, and cDNA bands were identified using a G;BOX EF imaging system (Syngene, Cambridge, UK). The result is shown in FIG. 7 .
- a sample was treated with the 30% ethanol extract of Chrysanthemum prepared in Example 1-(2) at 1 or 10 ⁇ g/mL.
- the samples were treated for 24 hours, and then the cells were dissolved in an NP-40 buffer solution (ELPIS-Biotech) containing a proteinase inhibitor cocktail (Sigma, St. Louis, Mo., USA).
- the cells dissolved in the buffer solution were transferred to a 1.5 mL tube for centrifugation at 13,000 rpm for 10 minutes, and then only a supernatant was taken.
- the supernatant obtained previously was quantified by a Bradford method (Bio-Rad Laboratories Inc., Hercules, Calif., USA).
- the quantified protein was boiled for 5 minutes and isolated by electrophoresis with a 10% SDS-PAGE gel, and then the isolated proteins were transferred to a nitrocellulose membrane.
- p-mTOR, mTOR, p-4EBP1, 4EBP1, p-P70S6K and P70S6K and an ⁇ -tubulin primary antibody were diluted in 2.5% bovine serum albumin (BSA; bioWORLD, Dublin, Ohio, USA) at a ratio of 1:1000, and the proteins which were transferred to a nitrocellulose membrane were reacted at room temperature for 20 hours.
- BSA bovine serum albumin
- the nitrocellulose membrane was washed with Tris-buffer Saline Tween 20 (TBST) three times for 10 minutes.
- TBST Tris-buffer Saline Tween 20
- a secondary antibody recognizing the primary antibody was diluted in 2.5% BSA at a ratio of 1:5000, and reacted with the nitrocellulose membrane at room temperature for 2 hours, and then the nitrocellulose membrane was washed with TBST three times each for 10 minutes.
- Protein bands were detected with western blotting detection reagents (Amersham, Tokyo, Japan), and visualized using a G;BOX EF imaging system (Syngene). The result is shown in FIG. 8 .
- Example 2 To confirm an effect of increasing an expression level of SIRT1 by treatment of COS7 cells (ATCC) with 3,5-dicaffeoylquinic acid, the 3,5-dicaffeoylquinic acid obtained in Example 2 was treated at 5, 10, 20, 40 or 60 ⁇ g/mL by the same method as described in Experimental Example 1-(4), and the result is shown in FIG. 10 .
- Example 2 To confirm an effect of increasing an expression level of PGC-1 ⁇ by treatment of COS7 cells (ATCC) with 3,5-dicaffeoylquinic acid, the 3,5-dicaffeoylquinic acid obtained in Example 2 was treated at 5, 10, 20, 40 or 60 ⁇ g/mL by the same method as described in Experimental Example 1-(2), and the result is shown in FIG. 11 .
- L6 myoblasts which are muscle cells
- 3,5-dicaffeoylquinic acid the cells were treated with the 3,5-dicaffeoylquinic acid obtained in Example 2 at 1 or 10 ⁇ g/mL and an expression level of the p-mTOR protein was confirmed by the same method as described in Experimental Example 3. The result is shown in FIG. 13 .
- L6 myoblasts which are muscle cells
- the cells were treated with the 3,5-dicaffeoylquinic acid obtained in Example 2 at 10, 20 or 40 ⁇ g/mL, and then mRNA expression levels of MyoD and myogenin were confirmed by the same method as described in Experimental Example 4. The result is shown in FIG. 14 .
- mRNA expression levels of MyoD and myogenin which are main factors involved in muscle differentiation in the L6 muscle cells, were increased in a concentration-dependent manner by treatment with 3,5-dicaffeoylquinic acid.
- the 3,5-dicaffeoylquinic acid of the present invention has an excellent ability to promote muscle differentiation in muscle cells.
- compositions containing an extract and components of the present invention will be described below, but this is for specific description of the present invention without limitation thereto.
- the components were mixed, and then an airtight pouch was charged with the mixture, thereby preparing a powder.
- the components were mixed, and then tableted by a conventional method of preparing a tablet, thereby preparing a tablet.
- the components were mixed, and then a gelatin capsule was filled with the mixture by a conventional method of preparing a capsule, thereby preparing a capsule.
- the components were mixed, and then an injection was prepared to include the mixture of the components at the above-mentioned contents per ampoule (2 mL) by a conventional method of preparing an injection.
- each component was dissolved in distilled water, the lemon flavor was added in a sufficient amount, the distilled water was added to become a total volume to 100 mL, and the mixture was sterilized. A brown bottle was filled with the sterilized mixture, thereby preparing a liquid.
- Vitamin mixture q.s.
- a mixture of the vitamins and minerals was prepared by mixing components relatively suitable for health food as a preferable example, a mixing ratio of these components may be arbitrarily changed.
- the above-mentioned components were mixed by a conventional method of preparing health food, thereby preparing granules, which may be used to prepare a composition for health food according to a conventional method.
- the above-mentioned components were mixed by a conventional method of preparing a food drink and heated while stirring at 85° C. for approximately 1 hour, and the prepared solution was filtered, contained in a sterilized 2 L container, sealed, stored in a refrigerator, and then used to prepare a composition for a health drink of the present invention.
- a mixing ratio may be arbitrarily changed according to regional and national preferences such as the demand level, the country of demand, a purpose of use, etc.
- the nourishing toner may be prepared by a conventional method used in the cosmetics field.
- the skin toner may be prepared by a conventional method used in the cosmetics field.
- the nourishing toner may be prepared by a conventional method used in the cosmetics field.
- the skin toner may be prepared by a conventional method used in the cosmetics field.
- the skin toner may be prepared by a conventional method used in the cosmetics field.
- the skin toner may be prepared by a conventional method used in the cosmetics field.
- Components relatively suitable for a cosmetic composition were mixed as a preferable example, and may also be applied to various types of cosmetics including color cosmetics.
- the components may be used to prepare a medication to be thinly applied to a human body depending on its efficacy, that is, an ointment, and a mixing ratio may be arbitrarily changed according to regional and national preferences such as the demand level, the country of demand, a purpose of use, etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a composition for preventing or treating a muscle disorder, which includes a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1α, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance. In addition, the present invention is a natural substance and may be safely used without a side effect, and therefore may be used as a medication, food or a cosmetic.
Description
- This application is a divisional of U.S. application Ser. No. 16/474,528, filed Jun. 27, 2019, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/KR2017/013879, filed internationally on Nov. 30, 2017, which claims priority to and the benefit of Korean Patent Application No. 10-2016-0183649, filed on Dec. 30, 2016, the disclosures of which are incorporated herein by reference in their entirety.
- The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 717572000210SeqList.TXT, created Sep. 6, 2021, which is 2.78 kilobytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety.
- The present invention relates to a composition for preventing, improving or treating a muscle disorder or improving muscle function, and more particularly, to a composition for preventing, improving or treating a muscle disorder or improving muscle function, which includes 3,5-dicaffeoylquinic acid or a Chrysanthemum extract.
- Over the past 50 to 100 years, the decline in human physical activity has been known to be associated with an increased incidence of metabolic diseases such as type 2 diabetes, obesity, cardiovascular diseases, etc. The lack of physical activity is the fourth leading cause of death, as reported by the World Health Organization. Due to this phenomenon, organizations such as the World Health Organization, the American Heart Association and the British Heart Foundation recommend a minimum of 30 minutes of aerobic exercise for at least five days a week. In fact, it has been reported that exercise reduces the incidence of diabetes, obesity, breast cancer and colon cancer, and has a high therapeutic effect on depression (Br. J. Pharmacol., 170: 1153-1166, 2013; Am. J. Cardiol., 110: 58B-68B, 2012).
- Skeletal muscle fibers are generally classified as type 1 (oxidative/slow) and type 2 (glycolytic/fast) fibers, and muscle fibers exhibit significant differences in shrinkage, metabolism and susceptibility to fatigue. The
type 1 fiber has a large number of mitochondria and mainly uses an oxidative metabolism for energy generation, and therefore stably provides ATP for a long time to withstand fatigue. Therefore, muscle wasting does not occur in the skeletal muscles with a lot oftype 1 fibers (Muscle Nerve, 31: 339-348, 2005). Type 2 fibers have low contents of mitochondria and oxidases and are dependent on a glycolytic metabolism as a main energy source such that the fibers become easily tired. - Peroxisome Proliferator Activated Receptor δ (PPARδ) is a main transcription regulatory factor which is highly present in a skeletal muscle, particularly,
type 1 fiber (10 fold of PPARα, and 50 fold of PPARδ), activates enzymes involved in β-oxidation of a long-chain fatty acid to burn fats in adipose cells (Cell, 113: 159-170, 2003), and is the first transcription factor which promotestype 1 fibrosis. Such PPARδ is known to be involved in a complicated pathway for regulating mitochondrial biogenesis upon activation and promoting exercise performance and resistance to obesity (PLoS Biol., 2: 1532-1539, 2004). Therefore,type 1 fibers generated adaptively through exercise are known to be resistant to fatigue. However, it has been reported that the same effects have been exhibited even when overexpression of PPARδ is artificially overexpressed in muscles without 002exercise. As a result of artificially overexpression of PPARδ in mouse muscles, mitochondrial biogenesis was increased, and the expression of fatty acid beta-oxidase and an increase intype 1 muscle fibers led to 67% and 92% increases in time and a distance for continuous running, compared with normal rats, respectively (PLoS Biol., 2: 1532-1539, 2004). Therefore, when PPARδ is activated, the form of a muscle fiber may be changed, resulting in enhancement of exercise performance. - As one of the representative methods for enhancing exercise performance by promoting energy consumption, there is a method of producing ATP energy by increasing fatty acid oxidation by mitochondria. It has been discovered that the number and ability of mitochondria involved in this method are regulated by a peroxisome proliferator-activated receptor-
gamma coactivator 1 alpha (PGC-1α) coactivator, and PGC-1α activity is regulated by sirtuin 1 (SIRT1) (EMBO. J., 26:1913-1923, 2007, Cell Metab., 1: 361-370, 2005). - Muscle atrophy occurs by a gradual decrease in muscle mass, and refers to muscular weakness and degeneration (Cell, 119(7): 907-910, 2004). Muscle atrophy is promoted by inactivity, oxidative stress or chronic inflammation, and weakens muscle function and exercise performance (Clin. Nutr., 26(5): 524-534, 2007). The most important factor determining muscle function is muscle mass, which is maintained by a balance of protein synthesis and degradation. Muscle atrophy occurs when protein degradation happens more than protein synthesis (Int. J. Biochem. Cell Biol., 37(10): 1985-1996, 2005).
- When a transcription factor, forkhead box (FoxO), migrates into the nucleus from the cytoplasm, expression of E3 ubiquitin ligase factor atrogin-1 and muscle RING-finger protein-1 (MuRF-1), which are involved in protein degradation, is increased (Dis. Model. Mech., 6: 25-39, 2013). When their expression levels are increased, protein degradation in muscles is promoted, thereby reducing muscle mass. Therefore, the inhibition of atrogin-1 expression reduces a loss of the amount of muscular proteins to maintain normal muscle function.
- The scientific name of Chrysanthemum is Chrysanthemum morifolium Ramat., which is generally used for ornamental plants, for making Chrysanthemum tea using flower thereof, and for a salad, soup or alcohol (Edible Medicinal and Non-Medicinal Plants, 7: 250-269, 2012). It has been reported that Chrysanthemum has an antioxidative effect (Afr. J. Biotechnol., 10(82): 19197-19202, 2011), an anti-tuberculosis action (Biol. Pharm. Bull., 28(1):158-160, 2005), and an anticancer effect (Cancer Lett., 177: 7-12, 2002).
- It has been reported that 3,5-dicaffeoylquinic acid contained in Chrysanthemum has an antiviral effect (Biochem, Pharmacol., 49: 1165-1170, 1995), an antiallergic effect (J. Agric. Food Chem., 54: 2915-2920, 2006), and a neuroprotective effect (Phytother. Res., 19: 243-245, 2005).
- However, an exercise performance-enhancing effect of Chrysanthemum and 3,5-dicaffeoylquinic acid or effects of preventing and improving a muscle disorder have not been known yet.
- The present invention is directed to providing a pharmaceutical composition for preventing or treating a muscle disorder, which includes a Chrysanthemum extract as an active ingredient.
- The present invention is also directed to providing a pharmaceutical composition for preventing or treating a muscle disorder, which includes 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient:
- The present invention is also directed to providing a food composition for preventing or improving a muscle disorder, or improving muscle function, which contains a Chrysanthemum extract as an active ingredient.
- The present invention is also directed to providing a food composition for preventing or improving a muscle disorder, or improving muscle function, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- The present invention is also directed to providing a cosmetic composition for preventing or improving a muscle disorder, or improving muscle function, which contains a Chrysanthemum extract as an active ingredient.
- The present invention is also directed to providing a cosmetic composition for preventing or improving a muscle disorder, or improving muscle function, which contains a compound of Formula 1 as an active ingredient.
- The present invention is also directed to providing a pharmaceutical composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- The present invention is also directed to providing a pharmaceutical composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient:
- The present invention is also directed to providing a food composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- The present invention is also directed to providing a food composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- The present invention is also directed to providing a cosmetic composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- The present invention is also directed to providing a cosmetic composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of Formula 1 as an active ingredient.
- However, technical problems to be solved by the present invention are not limited to the above-mentioned problems, and other problems which are not mentioned can be clearly understood by those of ordinary skill in the art from the following descriptions.
- In one aspect, the present invention provides a pharmaceutical composition for preventing or treating a muscle disorder, which contains a Chrysanthemum extract as an active ingredient.
- In another aspect, the present invention provides a pharmaceutical composition for preventing or treating a muscle disorder, which contains 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
- In still another aspect, the present invention provides a food composition for preventing or improving a muscle disorder or improving muscle function, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- In yet another aspect, the present invention provides a cosmetic composition for preventing or improving a muscle disorder or improving muscle function, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- The Chrysanthemum extract may include 3,5-dicaffeoylquinic acid of
Formula 1 as an active ingredient. - The Chrysanthemum extract may be obtained by extracting Chrysanthemum using water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent.
- The Chrysanthemum extract may be obtained by extracting Chrysanthemum through subcritical fluid extraction, supercritical fluid extraction, or high-pressure extraction.
- As the 3,5-dicaffeoylquinic acid, a compound isolated from the Chrysanthemum extract, or a synthetic compound or a commercially available compound may be used.
- The muscle disorder may be a muscle disorder caused by a decrease in muscle function, muscle wasting or muscle degeneration.
- The muscle disorder may be one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia, cachexia and sarcopenia.
- The composition may promote formation of muscle fibers.
- In addition, the present invention provides a pharmaceutical composition for enhancing exercise performance, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- In addition, the present invention provides a food composition for enhancing exercise performance, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- In addition, the present invention provides a cosmetic composition for enhancing exercise performance, which contains a Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- The composition may have effects of increasing exercise endurance, reinforcing muscle strength, enhancing balance, and/or enhancing exercise adaptation.
- The composition may increase the oxidative metabolic function of mitochondria.
- The composition may promote formation of muscle fibers.
- The present invention relates to a composition for preventing and treating a muscle disorder containing a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as active ingredients, wherein the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of PPARδ and PGC-1α, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance.
-
FIG. 1 shows a result of measuring the activity of a PPARδ ligand-binding domain according to treatment with a Chrysanthemum optimized hot water extract and 10%, 30%, 50%, 70% and 90% ethanol extracts. -
FIG. 2 shows a result of measuring expression levels of PGC-1α according to treatment with a Chrysanthemum optimized hot water extract and 10%, 30%, 50%, 70% and 90% ethanol extracts. -
FIG. 3 shows a result of measuring the activity of a PPARδ ligand binding domain according to treatment with a 95% ethanol extract of Chrysanthemum. -
FIG. 4 shows a result of measuring an expression level of SIRT1 according to treatment with a 95% ethanol extract of Chrysanthemum. -
FIG. 5 shows a result of measuring an expression level of PGC-1α according to treatment with a 95% ethanol extract of Chrysanthemum. -
FIG. 6 shows a result of measuring an amount of mitochondrial biogenesis according to treatment with a 30% ethanol extract of Chrysanthemum. -
FIG. 7 shows a result of measuring mRNA expression levels of atrogin-1 and MuRF-1 according to treatment with a 30% ethanol extract of Chrysanthemum. -
FIG. 8 shows a result of measuring protein expression levels of mTOR, p70S6K and 4EBP1 according to treatment with a 30% ethanol extract of Chrysanthemum. -
FIG. 9 shows a result of measuring mRNA expression levels of MyoD and myogenin according to treatment with a 30% ethanol extract of Chrysanthemum. -
FIG. 10 shows a result of measuring an expression level of SIRT1 according to treatment with 3,5-dicaffeoylquinic acid. -
FIG. 11 shows a result of measuring an expression level of PGC-1α according to treatment with 3,5-dicaffeoylquinic acid. -
FIG. 12 shows a result of measuring mRNA expression levels of atrogin-1 and MuRF-1 according to treatment with 3,5-dicaffeoylquinic acid. -
FIG. 13 shows a result of measuring an mTOR protein expression level according to treatment with 3,5-dicaffeoylquinic acid. -
FIG. 14 shows a result of measuring mRNA expression levels of MyoD and myogenin according to treatment with 3,5-dicaffeoylquinic acid. - The inventors had discovered that a Chrysanthemum extract and 3,5-dicaffeoylquinic acid have an activity of forming muscle and an activity of enhancing exercise performance, and therefore the present invention was completed.
- The term “muscle” used herein encompasses to a tendon, a muscle and a cord, and the “muscle function” used herein refers to an ability of generating power by muscle contraction, and includes muscular strength, which is the ability of muscles to exert maximum contraction to overcome resistance, muscle endurance, which is the ability of muscles to show how long or how many contractions and relaxations are repeated with a given weight, and agility, which is the ability of exerting strong power within short time. Such muscle functions are governed by the liver and proportional to muscle mass, and the “improvement in muscle function” refers to more enhancement in muscle function.
- The term “exercise performance” used herein refer to a degree of rapidly, intensively, accurately, longer and smoothly performing an action when body actions shown in normal life or sports are explicitly divided into running, hopping, throwing and swimming, and is defined by parameters such as muscular strength, agility and endurance, and the “enhancement in exercise performance” refers to improvement or enhancement in exercise performance.
- Hereinafter, the present invention will be described in detail.
- The present invention provides a pharmaceutical composition for preventing or treating a muscle disorder containing a Chrysanthemum extract as an active ingredient.
- The Chrysanthemum extract may include 3,5-dicaffeoylquinic acid of
Formula 1 below as an active ingredient. - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, but the present invention is not limited thereto. Here, the leaves, stems, flowers, root, skin or fruit of the Chrysanthemum, or a mixture thereof may be subjected to extraction.
- Specifically, the Chrysanthemum extract may be extracted using water, an organic solvent having 1 to 4 carbon atoms or a mixture thereof as a solvent. Here, the organic solvent may be one or more selected from the group consisting of a C1 to C4 lower alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane and petroleum ether, but the present invention is not limited.
- In addition, the lower alcohol used in extraction of the Chrysanthemum is more preferably ethanol or methanol, and most preferably ethanol. Specifically, in the case of using ethanol as a solvent for extraction of the Chrysanthemum, when a 10 to 95% ethanol aqueous solution is used, an effect of enhancing exercise performance and an activity to inhibit muscular protein degradation may be more significantly exhibited in preparation of a Chrysanthemum extract. More specifically, when the Chrysanthemum extract is prepared, a 30 to 95% ethanol aqueous solution is preferably used as a solvent, but the present invention is not limited thereto.
- In extraction, dry Chrysanthemum may be ground, and then water, an alcohol or a mixture thereof is preferably added 2 to 20 fold, and more preferably, added 3 to 10 fold, the weight of the ground Chrysanthemum, but the present invention is not limited thereto. An extraction temperature is preferably 20 to 100° C., and more preferably 60 to 100° C., but the present invention is not limited thereto. The extraction time is preferably 1 to 10 hours, and more preferably 2 to 5 hours, but the present invention is not limited thereto. An extraction method can be any one of cold extraction, ultrasonic extraction and reflux cooling extraction, and the reflux cooling extraction is preferably used, but the present invention is not limited thereto. The number of extraction cycles is preferably 1 to 5 times, and more preferably 2 or 3 times, but the present invention is not limited thereto.
- In addition, the Chrysanthemum extract may be attained by ultra-high pressure extraction, subcritical fluid extraction or supercritical fluid extraction.
- The present invention may also provide a pharmaceutical composition for preventing or treating a muscle disorder, which contains a compound of Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient:
- The compound of
Formula 1 is called 3,5-dicaffeoylquinic acid. - The structural name of the 3,5-dicaffeoylquinic acid is (3R,5R)-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid, and corresponds to CAS No. 89919-62-0.
- As the compound of
Formula 1, a compound isolated or synthesized from a Chrysanthemum extract or may be a commercially-available compound may be used. - The composition according to the present invention may inhibit muscle loss. Specifically, as mRNA expression of atrogin-1 and MuRF1, which are the main biomarkers involved in muscle protein degradation, may be decreased, and mRNA expression of the mTOR protein, which is the main biomarker involved in formation of a muscle protein and myogenin and MyoD, which are biomarkers related to muscle differentiation, may be increased, the composition may be used in prevention or treatment of a muscle disorder.
- The muscle disorder of the present invention may be a muscle disorder caused by a decrease in muscle function, muscle wasting or muscle degeneration, which is a disease which has been reported in the art, and specifically, any one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia and sarcopenia, but the present invention is not limited thereto.
- The muscle wasting or degeneration is caused by an innate factor, an acquired factor, aging or the like, and the muscle wasting contributes to gradual loss of muscle mass, and weakening and degeneration of a muscle, particularly, a skeletal muscle, a voluntary muscle or a heart muscle.
- In the composition of the present invention, a content of the Chrysanthemum extract may be 1 to 100 μg/mL, and a content of the 3,5-dicaffeoylquinic acid may be 1 to 100 μM, but the present invention is not limited thereto.
- The pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be formulated in oral preparations such as a powder, a granule, a capsule, a suspension, an emulsion, a syrup and an aerosol, a preparation for external use, a suppository and a sterilized injection according to a conventional method, and may include a suitable carrier, excipient or diluent, which is conventionally used in preparation of a pharmaceutical composition for formulation.
- As the carrier, excipient or diluent, various compounds including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, or a mixture thereof may be used.
- The pharmaceutical composition may be prepared with a diluent or excipient such as a filler, a thickening agent, a binder, a wetting agent, a disintegrant or a surfactant, which is generally used in the preparation.
- A solid preparation for oral administration may be prepared by mixing at least one or more excipients such as starch, calcium borate, sucrose, lactose, and gelatin with the Chrysanthemum extract. In addition, other than a simple excipient, lubricants such as magnesium stearate, talc, etc. may also be used.
- A liquid preparation for oral administration may be a suspension, a liquid for internal use, an emulsion, or a syrup, and may include various excipients, for example, a wetting agent, a sweetening agent, a flavoring agent, a preservative, etc., other than a simple diluent frequently used, for example, water or liquid paraffin.
- Examples of preparations for non-oral administration may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilizing agent and a suppository. As the non-aqueous solvent or suspension, propylene glycol, polyethylene glycol, a vegetable oil such as olive oil, or an injectable ester such as ethyl oleate may be used. As a suppository base, Witepsol, Tween 61, cacao butter, laurin fat, or glycerogelatin may be used.
- A preferable dose of the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be determined by a patient's condition and body weight, severity of a disease, a drug type, an administration route and a duration, and may be suitably selected by those of ordinary skill in the art. However, for a preferable effect, the pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be administered daily at 0.0001 to 2,000 mg/kg, and preferably 0.001 to 2,000 mg/kg. The pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be administered once or in divided doses per day. However, the scope of the present invention is not limited by the dose.
- The pharmaceutical composition for preventing or treating a muscle disorder according to the present invention may be administered to mammals such as rats, mice, livestock and humans via various routes. The administration may be performed orally, intravenously, intramuscularly, subcutaneously, intrathecally, or intracerebroventricularly.
- The present invention provides a health functional food composition for preventing or improving a muscle disorder, which contains a Chrysanthemum extract as an active ingredient.
- In addition, the present invention provides a health functional food composition for preventing or improving a muscle disorder, which contains a compound of
Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient: - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above. As the 3,5-dicaffeoylquinic acid of
Formula 1, a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above. - The present invention provides a health functional food composition for preventing or improving a muscle disorder, which contains a Chrysanthemum extract as an active ingredient.
- The present invention also provides a food composition for preventing a muscle disorder or improving muscle function, which contains 3,5-dicaffeoylquinic acid of
Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- As the 3,5-dicaffeoylquinic acid of
Formula 1, a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above. - In the food composition for improving muscle function according to the present invention, when the Chrysanthemum extract or 3,5-dicaffeoylquinic acid is used as an additive for health functional food, it may be added alone or in combination with other food or food components, and may be suitably used according to a conventional method. A mixing amount of the active ingredient may be suitably determined according to a purpose of use, for example, for prevention, health care or treatment.
- A health functional food can be produced in the form of common food or beverage, as well as a powder, a granule, a pill, a tablet or a capsule.
- There is no particular limitation to a type of the food, and examples of food to which the material can be added may include meat, sausage, bread, chocolate, candy, snacks, confectionaries, pizza, ramen, other noodles, gums, dairy products including ice cream, soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, and may include all types of food in a conventional meaning.
- Generally, in preparation of food or a beverage, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid may be added at 15 parts by weight or less, and preferably, 10 parts by weight or less with respect to 100 parts by weight of the raw materials. However, in the case of long-term intake of the food for health and sanitary or health control, the amount may be in the range or less, and since the present invention uses a fraction obtained from a natural substance and thus there is no problem in stability, the food may be used in an amount higher than the above range.
- A beverage among the health functional food according to the present invention may contain various flavoring agents or a natural carbohydrate as an additional component like a conventional beverage. The above-described natural carbohydrate may be a monosaccharide such as glucose or fructose, a disaccharide such as maltose or sucrose, a polysaccharide such as dextrin or cyclodextrin, or a sugar alcohol such as xylitol, sorbitol or erythritol. As a sweetening agent, a natural sweetening agent such as thaumatin or a stevia extract, or a synthetic sweetening agent such as saccharine or aspartame may be used. A ratio of the natural carbohydrate may be approximately 0.01 to 0.04 g, and preferably, approximately 0.02 to 0.03 g, per 100 mL of the beverage according to the present invention.
- Other than the above-mentioned components, the health functional food for improving muscle function according to the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, a protective colloid thickening agent, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, and a carbonating agent used in carbonated drinks. Other than these, the composition for improving muscle function may contain flesh for producing natural fruit juice, fruit drinks and vegetable drinks. Such components may be used alone or in combination. A ratio of the additive is not limited, but is generally selected in a range of 0.01 to 0.1 part by weight with respect to 100 parts by weight of the health functional food of the present invention.
- The present invention provides a cosmetic composition for improving muscle function, which contains a Chrysanthemum extract as an active ingredient.
- In addition, the present invention provides a cosmetic composition for improving muscle function, which contains 3,5-dicaffeoylquinic acid of
Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- As the 3,5-dicaffeoylquinic acid of
Formula 1, a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above. - The cosmetic composition of the present invention may contain a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and also include a dermatologically acceptable excipient, and thus can be prepared in the form of a composition for basic cosmetics (toner, essence, cleanser such as cleansing foam or cleansing water, pack, and body oil), a composition for color cosmetics (foundation, lipstick, mascara, and makeup base), a composition for hair products (shampoo, rinse, hair conditioner, and hair gel) and soap.
- As the excipient, an emollient, a skin permeation enhancer, a colorant, fragrance, an emulsifier, a thickener or a solvent may be included, but the present invention is not limited thereto. In addition, a flavor, a colorant, an antibacterial agent, an antioxidant, a preservative and a moisturizer may be further included, and for improvement in physical properties, a thickening agent, inorganic salts, and synthetic polymer materials may be included. For example, when a cleanser or soap are prepared using the cosmetic composition of the present invention, it may be easily prepared by adding the Chrysanthemum extract or 3,5-dicaffeoylquinic acid to a conventional cleanser or soap base. A cream may be prepared by adding the Chrysanthemum extract, 3,5-dicaffeoylquinic acid or a salt thereof to a common oil-in-water (OW) cream base. Here, in addition to a fragrance, a chelating agent, a colorant, an antioxidant, a preservative, etc., a synthetic or natural substance such as a protein, a mineral or a vitamin may be further added to improve physical properties. A content of the Chrysanthemum extract or 3,5-dicaffeoylquinic acid contained in the cosmetic composition of the present invention is, but is not limited to, preferably 0.001 to 10 wt %, and more preferably 0.01 to 5 wt %, with respect to the total weight of the composition. When the content is less than 0.001 wt %, a desired antiaging or wrinkle-improving effect may not be expected, and when the content is more than 10 wt %, there may be difficulty in stability or formulation.
- The present invention provides a pharmaceutical composition for improving exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- The present invention also provides a pharmaceutical composition for improving exercise performance, which contains 3,5-dicaffeoylquinic acid of
Formula 1 or a pharmaceutically acceptable salt thereof. - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- As the 3,5-dicaffeoylquinic acid of
Formula 1, a compound isolated or synthesized from a Chrysanthemum extract or a commercially-available compound may be used, and details have been described above. - The composition may increase the oxidative metabolic function of mitochondria, and specifically, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid of the present invention may improve exercise performance by significantly increasing SIRT1 and PGC-1α expression levels in muscle cells.
- In addition, the composition may promote formation of muscle fibers, and specifically, the Chrysanthemum extract of the present invention may improve exercise performance by significantly increasing PPARδ activity.
- In addition, the composition may prevent or treat any one or more diseases selected from the group consisting of a degenerative disease, mitochondrial dysfunction, a decrease in endurance, a decrease in agility, lethargy, muscle disuse and depression as the enhancement in exercise performance is induced.
- The present invention provides a food composition for improving exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- In addition, the present invention provides a food composition for improving exercise performance, which contains 3,5-dicaffeoylquinic acid of
Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- As the 3,5-dicaffeoylquinic acid of
Formula 1, a compound isolated or synthesized from the Chrysanthemum extract or a commercially available compound may be used, and the 3,5-dicaffeoylquinic acid may be the same as described above. - The present invention provides a cosmetic composition for enhancing exercise performance, which contains a Chrysanthemum extract as an active ingredient.
- In addition, the present invention provides a cosmetic composition for enhancing exercise performance, which contains 3,5-dicaffeoylquinic acid of
Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - The Chrysanthemum may be a plant of the genus Chrysanthemum in the family Asteraceae, and is called Chrysanthemum morifolium, and the Chrysanthemum has been described above.
- As the 3,5-dicaffeoylquinic acid of
Formula 1, a compound isolated or synthesized from the Chrysanthemum extract or a commercially available compound may be used, and details are the same as described above. - Hereinafter, to help in understanding the present invention, exemplary examples will be suggested. However, the following examples are merely provided to more easily understand the present invention, and not to limit the present invention.
- Dry Chrysanthemum was ground with a mixer, 10 g of the ground Chrysanthemum sample was added to 100 mL of methanol, and was extracted while stirring at 28° C. for 180 minutes. The extracted sample was filtrated under reduced pressure using a Whatman No. 2 filter, and the resulting filtrate was concentrated using a vacuum rotary concentrator to remove a solvent component, thereby preparing a methanol extract of Chrysanthemum.
- A process was performed by the same method as described in Example 1-(1), except that 10%, 30%, 50%, 70%, 90% or 95% ethanol was used, and as a result, a 10%, 30%, 50%, 70%, 90% or 95% ethanol extract of Chrysanthemum was prepared.
- A process was performed by the same method as described in Example 1-(1), except that ethyl acetate was used, and as a result, an ethyl acetate extract of Chrysanthemum was prepared.
- A process was performed by the same method as described in Example 1-(1), except that hexane was used, and as a result, a hexane extract of Chrysanthemum was prepared.
- Dry Chrysanthemum was ground with a mixer, 10 g of the ground Chrysanthemum sample was added to 100 mL of water, and was extracted while stirring at 82° C. for 180 minutes. Afterward, a process was performed by the same method as described in Example 1-(1), and as a result, a hot water extract of Chrysanthemum was prepared.
- A process was performed by the same method as described in Example 1-(5), except that chloroform was used, and as a result, a chloroform extract of Chrysanthemum was prepared.
- Dry Chrysanthemum was ground with a mixer, and 1 g of the ground Chrysanthemum sample and 76 mL of 18% ethanol were put into a polyethylene pack, and extracted using an ultra-high pressure extractor (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan). Conditions for ultra-high pressure extraction included an extraction pressure of 320 MPa and an extraction time of 5 minutes. The extracted sample was filtered with a Whatman No. 2 filter, the resulting filtrate was concentrated using a vacuum rotary concentrator to remove a solvent component, thereby preparing an ultra-high pressure extract of Chrysanthemum.
- Dry Chrysanthemum was ground with a mixer, 1 g of the ground Chrysanthemum sample was charged into a sample cartridge, and extracted using a supercritical fluid extractor (SFX 3560, Isco Inc., Lincoln, Nebr., USA). Conditions for supercritical fluid extraction included an extraction pressure of 20 MPa, an extraction temperature of 60° C., a supercritical CO2 flow rate of 60 mL/min, and an extraction time of 60 minutes. When the supercritical fluid extraction was completed, a pressure of the extractor was reduced to terminate a supercritical fluid state, thereby obtaining a Chrysanthemum supercritical fluid extract.
- Dry Chrysanthemum was ground with a mixer, 50 g of the ground Chrysanthemum and 1 L of water were put into a subcritical water reactor in a subcritical extractor (Biovan, Gyeonggi, Korea) and then sealed. After sealing, a temperature of the reactor was increased up to 200° C., and when the temperature of the reactor reached 200° C., the temperature was maintained for 20 minutes for extraction. After 20 minutes, the extract was transferred to a storage tank to which cold water was provided to be rapidly cooled down to 30° C., and to isolate a suspended residue, only a supernatant was subjected to centrifugation at 3,600 rpm for 30 minutes. A solvent was thoroughly removed using a freeze dryer (IlShin Lab Co. Ltd., Seoul, Korea), thereby obtaining a subcritical extract of Chrysanthemum.
- The ethanol extract of Chrysanthemum prepared in Example 1-(2) was dissolved in 2 L of water, and isolated in three different solvents using ethyl acetate and n-butanol. The n-butanol solvent portion was loaded in an RP-18-filled column, and fractionated with a solvent system which changes a methanol ratio from 15 to 70%. According to the fractionation sequence, 16 subfractions were obtained. The seventh fraction was concentrated again using a vacuum rotary concentrator to remove a solvent component. The concentrate was loaded in a RP-18-filled column, and then fractioned with methanol. According to the fractionation sequence, 6 subfractions were obtained. Among these, 3,5-dicaffeoylquinic acid, which is the compound of the following
Formula 1, was isolated and purified from the second fraction. - Dry Chrysanthemum was ground with a mixer, 10 g of the ground Chrysanthemum sample was added to 100 mL of 30% ethanol and extracted at 70° C. for 3 hours. The extracted sample was filtrated under low pressure with a Whatman No. 2 filter, the filtered extract solution was concentrated with a vacuum rotary concentrator to remove a solvent component, thereby preparing a 30% ethanol extract of Chrysanthemum, and here, a yield of the Chrysanthemum extract was 23.24%. A content of 3,5-dicaffeoylquinic acid, which is the compound of the following
Formula 1, in the Chrysanthemum extract was analyzed by high-performance liquid chromatography (HPLC, YL9100 HPLC system; Younglin Instruments CO., Ltd., Gyeonggi, Korea). For HPLC analysis, 0.01% phosphoric acid and an acetonitrile solvent were used, and a 30% ethanol extract of Chrysanthemum was analyzed at a wavelength of 330 nm and a flow rate of 1.0 mL/min. The 3.5-dicaffeoylquinic acid was detected at a retention time of 11 minutes, and contained at 2.17% in the 30% ethanol extract of Chrysanthemum. - An experiment was performed by a known method using a vector having a luciferase gene under the control of a plasmid expressing PPARδ and PPRE (Cell, 68: 879-887, 1992; J. Biol. Chem., 272: 25252-25259, 1997).
- COS7 cells (CV-1 in Origin Simian-7, ATCC, Manassas, Va., USA) which do not express a PPAR-related gene were cultured in Dulbecco Modified Eagle Medium (DMEM, Hyclone, Logan, Utah, USA) containing 10% fetal bovine serum (FBS, Gibco, Gaithersburg, Md., USA), and then cultured in a 24-well plate for 5 hours or longer. For transfection, a plus reagent (Aptabio, Gyeonggi, Korea), a PPARδ plasmid and a pFR-luciferase vector (Stratagene, La Jolla, Calif., USA) were mixed together with serum-free DMEM (Hyclone), incubated for 15 minutes, mixed with a Lipofecter reagent (Aptabio), incubated again at room temperature for 15 minutes, and then dropped on the cells. After 4 hours, the medium was replaced with a 10% FBS (Gibco)-containing DMEM (Hyclone), and stabilized for 24 hours. The 10%, 30%, 50%, 70% or 90% ethanol extract of Chrysanthemum, which were prepared in Example 1-(2), or the hot water extract of Chrysanthemum, which was prepared in Example 1-(5), were treated at 10 μg/mL, and a degree of activating a ligand binding domain was quantified by adding a luciferase substrate (Promega, Madison, Wis., USA) and using a Microlumateplus LB 96V luminometer (Berthlod, Wildbab, Germany). The result is shown in
FIG. 1 . - As a result, as shown in
FIG. 1 , the hot water extract of Chrysanthemum, and the 10%, 30%, 50% and 70% ethanol extracts significantly increased PPARδ activity (*p<0.05). This means that the Chrysanthemum extract of the present invention is a ligand of PPARδ and has an excellent ability to activate PPARδ. - To confirm an effect of increasing an expression level of PGC-1α by treatment of COS7 cells with a Chrysanthemum extract, COS7 cells (ATCC) were transfected with a pTA-Luc-PGC-1α plasmid (Addgene) by the same method as described in Experimental Example 1-(1). Here, 10%, 30%, 50%, 70% and 90% ethanol extracts of Chrysanthemum, which were prepared in Example 1-(2), and the hot water extract of Chrysanthemum, which was prepared in Example 1-(5), were treated at 10 μg/mL. The result is shown in
FIG. 2 . - As a result, as shown in
FIG. 2 , the hot water extract of Chrysanthemum and 10%, 30%, 50% and 70% ethanol extracts significantly increased the activity of PGC-1α, which is a main factor involved in mitochondrial biogenesis (*p<0.05). This means that an ability of the Chrysanthemum extract of the present invention to promote mitochondrial biogenesis by activating PGC-1α is excellent. - To confirm an effect of increasing PPARδ activity by treatment with a 95% ethanol extract of Chrysanthemum in COS7 cells (ATCC), a degree of activating a ligand binding domain when the 95% ethanol extract of Chrysanthemum, prepared in Example 1-(2), was treated at 5, 10, 20 or 30 μg/mL by the same method as described in Experimental Example 1-(1) is shown in
FIG. 3 . - As a result, as shown in
FIG. 3 , the 95% ethanol extract of Chrysanthemum increased PPARδ activity in a concentration-dependent manner, and compared with a control group, exhibited a significant difference (**p<0.01). This means that the 95% ethanol extract of Chrysanthemum according to the present invention is a ligand of PPARδ and has an excellent ability to activate PPARδ. - To confirm an effect of increasing an expression level of SIRT1 by treatment of COS7 cells (ATCC) with a Chrysanthemum extract, COS7 cells (ATCC) were transfected with a pTA-Luc-SIRT1 plasmid (Addgene) by the same method as described in Experimental Example 1-(1). Here, the 95% ethanol extract of Chrysanthemum prepared in Example 1-(2) was treated at 20, 30 or 40 μg/mL, and the result is shown in
FIG. 4 . - As a result, as shown in
FIG. 4 , the 95% ethanol extract of Chrysanthemum significantly increased an expression level of SIRT1, which is a main factor involved in mitochondrial biogenesis (**p<0.01). This means that the 95% ethanol extract of Chrysanthemum according to the present invention increases mitochondrial biogenesis, and has an excellent ability to increase exercise performance. - To confirm an effect of increasing an expression level of PGC-1α by treatment of COST cells (ATCC) with the 95% ethanol extract of Chrysanthemum, the 95% ethanol extract of Chrysanthemum, prepared in Example 1-(2), was treated at 10 or 40 μg/mL by the same method as described in Experimental Example 1-(2). The result is shown in
FIG. 5 . - As a result, as shown in
FIG. 5 , 40 μg/mL of the 95% ethanol extract of Chrysanthemum significantly increased PGC-1α activity, which is a main factor involved in mitochondrial biogenesis (**p<0.01). This means that the 95% ethanol extract of Chrysanthemum according to the present invention activates PGC-1α and thus has an excellent ability to promote mitochondrial biogenesis. - L6 myoblasts (ATCC), which are muscle cells, were added at 1×105 cell/mL to a 6-well plate with 10% FBS (Gibco)-containing DMEM (Hyclone). When the cell density reached approximately 80 to 85%, the medium in the well was removed, and then the cells were treated with the 30% ethanol extract of Chrysanthemum prepared in Example 1-(2), which was dissolved in 2% HS (Hyclone)-containing DMEM (Hyclone) at 5, 10 or 20 μg/mL, to induce myotube differentiation. Here, the differentiation was performed for total of 6 days by replacing the medium and a sample with fresh ones every two days. After the differentiation induction, the medium was suctioned, and 100 nM Mitotracker (Thermo Fisher Scientific Inc., Waltham, Mass., USA) dissolved in DMEM (Hyclone) was treated for 30 minutes. The medium was removed, 1 mL of a methanol solvent was added to each well, and fluorescence was measured at an absorption wavelength of 490 nm and an emission wavelength of 516 nm using a microplate reader (Versa Max, Sunnyvale, Calif., USA). The result is shown in
FIG. 6 . - As a result, as shown in
FIG. 6 , the 30% ethanol extract of Chrysanthemum significantly increased an amount of mitochondria in a muscle (*p<0.05, **p<0.01). This means that the 30% ethanol extract of Chrysanthemum according to the present invention promotes mitochondrial biogenesis and has an excellent ability to increase exercise performance. - L6 myoblasts (ATCC), which are muscle cells, were added at 1×105 cell/mL to a 6-well plate with 10% FBS (Gibco)-containing DMEM (Hyclone). When the cell density reached approximately 80 to 85%, the medium in the well was removed, the cells were treated with 2% HS (Hyclone)-containing DMEM (Hyclone) to induce myotube differentiation. The differentiation was performed for total of 6 days by replacing the medium and a sample with fresh ones every two days. After differentiation, the 30% ethanol extract of Chrysanthemum prepared in Example 1-(2) was dissolved in DMEM (Hyclone) containing 50 ng/mL tumor necrosis factor alpha (TNF-α; PeproTech, Rocky Hills, N.J., USA) at 1 or 10 μg/mL, and used to treat the cells. After 6 hours, total RNA was isolated with a TRIzol reagent (Takara, Shiga, Japan). The isolated total RNA was quantified using a NanoDrop 1000 (Thermo Fisher Scientific Inc.). cDNA was synthesized from 16 μL of the quantified RNA using a Reverse Transcriptase Premix (ELPIS-Biotech, Daejeon, Korea) and a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, Calif., USA) under conditions of 42° C. for 55 minutes and 70° C. for 15 minutes. PCR was performed in 30 cycles using 4 μL out of 16 μL of the produced cDNA, specific primers (Bioneer, Daejeon, Korea) below and a PCR premix (ELPIS-Biotech) at 95° C. for 30 seconds, 60° C. for 1 minutes, and 72° C. for 1 minute. The sequences of the primers used in the PCR are shown in Table 1 below. The cDNA amplified by PCR was isolated by electrophoresis using a 1.5% agarose gel, and cDNA bands were identified using a G;BOX EF imaging system (Syngene, Cambridge, UK). The result is shown in
FIG. 7 . -
TABLE 1 Name of Primer target gene Primer sequence direction Sequence No. Atrogin-1 5′-CCCTGAGTGGCATCGCCCAA-3′ Forward SEQ ID NO: 1 5′-AGGTCCCGCCCATCGCTCA-3′ Reverse SEQ ID NO: 2 MuRF-1 5′-TCTACTCGGCCACAGGCGCT-3′ Forward SEQ ID NO: 3 5′-CTTGACAGCTCCCGCCGCAA-3′ Reverse SEQ ID NO: 4 β- Actin 5′-AGCCATGTACGTAGCCATCC-3′ Forward SEQ ID NO: 5 5′-CTCTCAGCTGTGGTGCTGAA-3′ Reverse SEQ ID NO: 6 - Consequently, as shown in
FIG. 7 , expression levels of the major biomarkers related to muscle protein degradation, such as atrogin-1 and MuRF-1, significantly increased (##p<0.01) due to TNF-α, and the mRNA expression levels of atrogin-1 and MuRF-1, increased by TNF-α, were significantly decreased (**p<0.01) by treating the 30% ethanol extract of Chrysanthemum. This means that the 30% ethanol extract of Chrysanthemum according to the present invention has an excellent ability to inhibit muscle protein degradation in muscle cells. - To confirm the muscle protein expression-increasing activity of a Chrysanthemum extract in L6 myoblasts (ATCC), which are muscle cells, after differentiation by the same method as described in Experimental Example 2, a sample was treated with the 30% ethanol extract of Chrysanthemum prepared in Example 1-(2) at 1 or 10 μg/mL. The samples were treated for 24 hours, and then the cells were dissolved in an NP-40 buffer solution (ELPIS-Biotech) containing a proteinase inhibitor cocktail (Sigma, St. Louis, Mo., USA). The cells dissolved in the buffer solution were transferred to a 1.5 mL tube for centrifugation at 13,000 rpm for 10 minutes, and then only a supernatant was taken. The supernatant obtained previously was quantified by a Bradford method (Bio-Rad Laboratories Inc., Hercules, Calif., USA). The quantified protein was boiled for 5 minutes and isolated by electrophoresis with a 10% SDS-PAGE gel, and then the isolated proteins were transferred to a nitrocellulose membrane. p-mTOR, mTOR, p-4EBP1, 4EBP1, p-P70S6K and P70S6K and an α-tubulin primary antibody were diluted in 2.5% bovine serum albumin (BSA; bioWORLD, Dublin, Ohio, USA) at a ratio of 1:1000, and the proteins which were transferred to a nitrocellulose membrane were reacted at room temperature for 20 hours. After the reaction with the primary antibody, the nitrocellulose membrane was washed with Tris-buffer Saline Tween 20 (TBST) three times for 10 minutes. After washing, a secondary antibody recognizing the primary antibody was diluted in 2.5% BSA at a ratio of 1:5000, and reacted with the nitrocellulose membrane at room temperature for 2 hours, and then the nitrocellulose membrane was washed with TBST three times each for 10 minutes. Protein bands were detected with western blotting detection reagents (Amersham, Tokyo, Japan), and visualized using a G;BOX EF imaging system (Syngene). The result is shown in
FIG. 8 . - As shown in
FIG. 8 , protein expression levels of p-mTOR, p-4EBP1 and p-P70S6K, which are main biomarkers related to muscle protein production, were significantly decreased by TNF-α (##p<0.01), and the p-mTOR, p-4EBP1 and p-P70S6K protein expression levels, which were reduced by TNF-α, were significantly increased by the treatment with the 30% ethanol extract of Chrysanthemum (**p<0.01). This means that the 30% ethanol extract of Chrysanthemum of the present invention has an excellent ability to increase muscle production in muscle cells. - To confirm the muscle differentiation-promoting activity of a Chrysanthemum extract in L6 myoblasts (ATCC), which are muscle cells, the cells were treated with the 30% ethanol extract of Chrysanthemum, prepared in Example 1-(2), at 5, 10 or 20 μg/mL to induced myotube differentiation by the same method as described in Experimental Example 1-(6). RT-PCR was performed with specific primers (Bioneer) by the same method as described in Experimental Example 2, and the result is shown in
FIG. 9 . -
TABLE 2 Name of Primer target gene Primer sequence direction Sequence No. MyoD 5′-GGATGGTGCCCCTGGGTCCT-3′ Forward SEQ ID NO: 7 5′-TGGCCTTCGCTGTGAGTCGC-3′ Reverse SEQ ID NO: 8 Myogenin 5′-TGGGCTGCCACAAGCCAGAC-3′ Forward SEQ ID NO: 9 5′-CAGCCCAGCCACTGGCATCA-3′ Reverse SEQ ID NO: 10 β- Actin 5′-CTGTGTGGATTGGTGGCTCTAT-3′ Forward SEQ ID NO: 11 5′-GTGTAAAACGCAGCTCAGTAACA-3′ Reverse SEQ ID NO: 12 - As shown in
FIG. 9 , when the 30% ethanol extract of Chrysanthemum was treated, mRNA expression of MyoD and myogenin, which are main genes related to differentiation activity of muscle cells, was significantly increased (**p<0.01). This means that the 30% ethanol extract of Chrysanthemum of the present invention has an excellent effect of promoting muscle differentiation in muscle cells. - To confirm an effect of increasing an expression level of SIRT1 by treatment of COS7 cells (ATCC) with 3,5-dicaffeoylquinic acid, the 3,5-dicaffeoylquinic acid obtained in Example 2 was treated at 5, 10, 20, 40 or 60 μg/mL by the same method as described in Experimental Example 1-(4), and the result is shown in
FIG. 10 . - As a result, as shown in
FIG. 10 , when 3,5-dicaffeoylquinic acid was treated at 20, 40 or 60 μg/mL, the expression level of SIRT1 was significantly increased (**p<0.01). This means that the 3,5-dicaffeoylquinic acid of the present invention activates SIRT1 and thus has an excellent ability to promote mitochondrial biogenesis. - To confirm an effect of increasing an expression level of PGC-1α by treatment of COS7 cells (ATCC) with 3,5-dicaffeoylquinic acid, the 3,5-dicaffeoylquinic acid obtained in Example 2 was treated at 5, 10, 20, 40 or 60 μg/mL by the same method as described in Experimental Example 1-(2), and the result is shown in
FIG. 11 . - As a result, as shown in
FIG. 11 , when 3,5-dicaffeoylquinic acid was treated at 5, 10, 20, 40 or 60 μg/mL, an expression level of PGC-1α, which is a main factor involved in mitochondrial biogenesis was significantly increased (**p<0.01). This means that the 3,5-dicaffeoylquinic acid of the present invention activates PGC-1α and thus has excellent ability to promote mitochondrial biogenesis. - To confirm muscle protein degradation-inhibiting activity by treatment of L6 myoblasts (ATCC), which are muscle cells, with 3,5-dicaffeoylquinic acid, the cells were treated with the 3,5-dicaffeoylquinic acid obtained in Example 2 at 1 or 10 μg/mL, and then mRNA expression levels of atrogin-1 and MuRF-1 were confirmed by the same method as described in Experimental Example 2. The result is shown in
FIG. 12 . - As a result, as shown in
FIG. 12 , expression levels of atrogin-1 and MuRF-1, which are the main biomarkers involved in muscle protein degradation, were increased by TNF-α, and mRNA expression of atrogin-1 and MuRF-1, which were increased by TNF-α, was decreased in a concentration dependent manner by treatment with 3,5-dicaffeoylquinic acid. This means that the 3,5-dicaffeoylquinic acid of the present invention has an excellent ability to inhibit muscle protein degradation in muscle cells. - To confirm muscle protein synthesis-promoting activity by treatment of L6 myoblasts (ATCC), which are muscle cells, with 3,5-dicaffeoylquinic acid, the cells were treated with the 3,5-dicaffeoylquinic acid obtained in Example 2 at 1 or 10 μg/mL and an expression level of the p-mTOR protein was confirmed by the same method as described in Experimental Example 3. The result is shown in
FIG. 13 . - As a result, as shown in
FIG. 13 , expression levels of p-mTOR, p-4EBP1 and p-P70S6K proteins, which are the main biomarkers involved in muscle protein production, were decreased by TNF-α, and an expression level of the p-mTOR protein, which was decreased by treatment with 3,5-dicaffeoylquinic acid, was increased in a concentration-dependent manner. This means that the 3,5-dicaffeoylquinic acid of the present invention has an excellent ability to increase muscle production in muscle cells. - To confirm muscle protein synthesis-promoting activity by treatment of L6 myoblasts (ATCC), which are muscle cells, with 3,5-dicaffeoylquinic acid, the cells were treated with the 3,5-dicaffeoylquinic acid obtained in Example 2 at 10, 20 or 40 μg/mL, and then mRNA expression levels of MyoD and myogenin were confirmed by the same method as described in Experimental Example 4. The result is shown in
FIG. 14 . - As a result, as shown in
FIG. 14 , mRNA expression levels of MyoD and myogenin, which are main factors involved in muscle differentiation in the L6 muscle cells, were increased in a concentration-dependent manner by treatment with 3,5-dicaffeoylquinic acid. This means that the 3,5-dicaffeoylquinic acid of the present invention has an excellent ability to promote muscle differentiation in muscle cells. - Hereinafter, preparation examples of compositions containing an extract and components of the present invention will be described below, but this is for specific description of the present invention without limitation thereto.
- 20 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 100 mg of fructose hydrate
- 10 mg of talc
- The components were mixed, and then an airtight pouch was charged with the mixture, thereby preparing a powder.
- 10 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 100 mg of corn starch
- 100 mg of fructose hydrate
- 2 mg of magnesium stearate
- The components were mixed, and then tableted by a conventional method of preparing a tablet, thereby preparing a tablet.
- 10 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 3 mg of microcrystalline cellulose
- 14.8 mg of fructose hydrate
- 0.2 mg of magnesium stearate
- The components were mixed, and then a gelatin capsule was filled with the mixture by a conventional method of preparing a capsule, thereby preparing a capsule.
- 10 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 180 mg of mannitol
- 2974 mg of sterilized distilled water for injection
- 26 mg of sodium monohydrogen phosphate
- The components were mixed, and then an injection was prepared to include the mixture of the components at the above-mentioned contents per ampoule (2 mL) by a conventional method of preparing an injection.
- 10 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 10 mg of isomerized sugar
- 5 mg of mannitol
- Distilled water q.s.
- Lemon flavor q.s.
- According to a conventional preparation method, each component was dissolved in distilled water, the lemon flavor was added in a sufficient amount, the distilled water was added to become a total volume to 100 mL, and the mixture was sterilized. A brown bottle was filled with the sterilized mixture, thereby preparing a liquid.
- 10 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- Vitamin mixture q.s.
- 70 μg of vitamin A acetate
- 1.0 mg of vitamin E
- 0.13 mg of vitamin B1
- 0.15 mg of vitamin B2
- 0.5 mg of vitamin B6
- 0.2 μg of vitamin B12
- 10 mg of vitamin C
- 10 μg of biotin
- 1.7 mg of nicotinamide
- 50 μg of folic acid
- 0.5 mg of calcium pantothenate
- Mineral mixture q.s.
- 1.75 mg of ferrous sulfate
- 0.82 mg of zinc oxide
- 25.3 mg of magnesium carbonate
- 15 mg of monopotassium phosphate
- 55 mg of dicalcium phosphate
- 30 mg of potassium citrate
- 100 mg of calcium carbonate
- 24.8 mg of magnesium chloride
- Although a mixture of the vitamins and minerals was prepared by mixing components relatively suitable for health food as a preferable example, a mixing ratio of these components may be arbitrarily changed. The above-mentioned components were mixed by a conventional method of preparing health food, thereby preparing granules, which may be used to prepare a composition for health food according to a conventional method.
- 10 mg of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 15 g of vitamin C
- 100 g of vitamin E (powder)
- 19.75 g of ferrous lactose
- 3.5 g of zinc oxide
- 3.5 g of nicotinamide
- 0.2 g of vitamin A
- 0.25 g of vitamin B1
- 0.3 g of vitamin B2
- Distilled water q.s.
- The above-mentioned components were mixed by a conventional method of preparing a food drink and heated while stirring at 85° C. for approximately 1 hour, and the prepared solution was filtered, contained in a sterilized 2 L container, sealed, stored in a refrigerator, and then used to prepare a composition for a health drink of the present invention.
- Although components relatively suitable for a favorite drink were mixed as a preferable example, a mixing ratio may be arbitrarily changed according to regional and national preferences such as the demand level, the country of demand, a purpose of use, etc.
- 2.0 wt % of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 5.0 wt % of squalene
- 4.0 wt % of cera
- 1.5 wt % of
polysorbate 60 - 1.5 wt % of sorbitan sesquioleate
- 0.5 wt % of liquid paraffin
- 5.0 wt % of caprylic/capric triglyceride
- 3.0 wt % of glycerin
- 3.0 wt % of butylene glycol
- 3.0 wt % of propylene glycol
- 0.1 wt % of carboxy vinyl polymer
- 0.2 wt % of triethanolamine
- Preservative, colorant, flavor q.s.
- 100 wt % of distilled water
- Although components relatively suitable for a nourishing toner were mixed as a preferable example, a mixing ratio may be arbitrarily changed. The nourishing toner may be prepared by a conventional method used in the cosmetics field.
- 2.0 wt % of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 3.0 wt % of glycerin
- 2.0 wt % of butylene glycol
- 2.0 wt % of propylene glycol
- 0.1 wt % of carboxy vinyl polymer
- 0.2 wt % of PEG 12 nonylphenylether
- 0.4 wt % of
polysorbate 80 - 10.0 wt % of ethanol
- 0.1 wt % of triethanolamine
- Preservative, colorant, flavor q.s.
- 100 wt % of distilled water
- Although components relatively suitable for a skin toner were mixed as a preferable example, a mixing ratio may be arbitrarily changed. The skin toner may be prepared by a conventional method used in the cosmetics field.
- 2.0 wt % of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 1.5 wt % of
polysorbate 60 - 0.5 wt % of sorbitan sesquioleate
- 2.0 wt % of PEG60 hydrogenated castor oil
- 10 wt % of liquid paraffin
- 5.0 wt % of squalene
- 5.0 wt % of caprylic/capric triglyceride
- 5.0 wt % of glycerin
- 3.0 wt % of butylene glycol
- 3.0 wt % of propylene glycol
- 0.2 wt % of triethanolamine
- Preservative q.s.
- Colorant q.s.
- Flavor q.s.
- 100 wt % of distilled water
- Although components relatively suitable for a nourishing cream were mixed as a preferable example, a mixing ratio may be arbitrarily changed. The nourishing toner may be prepared by a conventional method used in the cosmetics field.
- 1.0 wt % of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 10.0 wt % of cera
- 1.5 wt % of
polysorbate 60 - 2.0 wt % of PEG 12 nonylphenylether
- 0.8 wt % of sorbitan sesquioleate
- 40.0 wt % of liquid paraffin
- 5.0 wt % of squalene
- 4.0 wt % of caprylic/capric triglyceride
- 5.0 wt % of glycerin
- 3.0 wt % of butylene glycol
- 3.0 wt % of propylene glycol
- 0.2 wt % of triethanolamine
- Preservative, colorant, flavor q.s.
- 100 wt % of distilled water
- Although components relatively suitable for a massage cream were mixed as a preferable example, a mixing ratio may be arbitrarily changed. The skin toner may be prepared by a conventional method used in the cosmetics field.
- 1.0 wt % of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 13.0 wt % of polyvinyl alcohol
- 0.2 wt % of sodium carboxymethylcellulose
- 5.0 wt % of glycerin
- 0.1 wt % of allantoin
- 6.0 wt % of ethanol
- 0.3 wt % of PEG 12 nonylphenylether
- 0.3 wt % of
polysorbate 60 - Preservative, colorant, flavor q.s.
- 100 wt % of distilled water
- Although components relatively suitable for a pack were mixed as a preferable example, a mixing ratio may be arbitrarily changed. The skin toner may be prepared by a conventional method used in the cosmetics field.
- 0.5 wt % of Chrysanthemum extract or 3,5-dicaffeoylquinic acid
- 0.05 wt % of ethylenediamine sodium acetate
- 5.0 wt % of glycerin
- 0.3 wt % of carboxyvinyl polmyer
- 5.0 wt % of ethanol
- 0.5 wt % of PEG60 hydrogenated castor oil
- 0.3 wt % of triethanolamine
- Preservative, colorant, flavor q.s.
- 100 wt % of distilled water
- Although components relatively suitable for a gel were mixed as a preferable example, a mixing ratio may be arbitrarily changed. The skin toner may be prepared by a conventional method used in the cosmetics field.
- Components relatively suitable for a cosmetic composition were mixed as a preferable example, and may also be applied to various types of cosmetics including color cosmetics. The components may be used to prepare a medication to be thinly applied to a human body depending on its efficacy, that is, an ointment, and a mixing ratio may be arbitrarily changed according to regional and national preferences such as the demand level, the country of demand, a purpose of use, etc.
- It should be understood by those of ordinary skill in the art that the above description of the present invention is exemplary, and the exemplary embodiments disclosed herein can be easily modified into other specific forms without departing from the technical spirit or essential features of the present invention. Therefore, the exemplary embodiments described above should be interpreted as illustrative and not limited in any aspect.
Claims (14)
2. The method according to claim 1 , wherein the improving exercise performance comprises preventing or treating any of one or more diseases selected from the group consisting of a degenerative disease, mitochondrial dysfunction, a decrease in endurance, a decrease in agility, lethargy, muscle disuse and depression.
3. The method according to claim 1 , wherein the administration increases oxidative metabolic function of mitochondria, increases SIRT1 and PGC-1α expression levels in muscle cells, promotes formation of muscle fibers, or increases PPARδ activity.
4. The method according to claim 1 , wherein the Chrysanthemum extract is a Chrysanthemum morifolium extract.
5. The method according to claim 1 , wherein the Chrysanthemum extract is obtained by extracting Chrysanthemum using water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent.
6. The method according to claim 1 , wherein the Chrysanthemum extract is obtained by extracting Chrysanthemum by subcritical fluid extraction, supercritical fluid extraction or ultra-high pressure extraction.
7. The method according to claim 1 , wherein the 3,5-dicaffeoylquinic acid is a compound isolated from a Chrysanthemum extract.
9. The method according to claim 2 , wherein the administration increases oxidative metabolic function of mitochondria, increases SIRT1 and PGC-1α expression levels in muscle cells, promotes formation of muscle fibers, or increases PPARδ activity.
10. The method according to claim 2 , wherein the Chrysanthemum extract is a Chrysanthemum morifolium extract.
11. The method according to claim 2 , wherein the Chrysanthemum extract is obtained by extracting Chrysanthemum using water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent.
12. The method according to claim 2 , wherein the Chrysanthemum extract is obtained by extracting Chrysanthemum by subcritical fluid extraction, supercritical fluid extraction or ultra-high pressure extraction.
13. The method according to claim 2 , wherein the 3,5-dicaffeoylquinic acid is a compound isolated from a Chrysanthemum extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/479,990 US20210401916A1 (en) | 2016-12-30 | 2021-09-20 | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160183649 | 2016-12-30 | ||
KR10-2016-0183649 | 2016-12-30 | ||
PCT/KR2017/013879 WO2018124508A1 (en) | 2016-12-30 | 2017-11-30 | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
US201916474528A | 2019-06-27 | 2019-06-27 | |
US17/479,990 US20210401916A1 (en) | 2016-12-30 | 2021-09-20 | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/013879 Division WO2018124508A1 (en) | 2016-12-30 | 2017-11-30 | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
US16/474,528 Division US11160840B2 (en) | 2016-12-30 | 2017-11-30 | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210401916A1 true US20210401916A1 (en) | 2021-12-30 |
Family
ID=62710683
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/474,528 Active US11160840B2 (en) | 2016-12-30 | 2017-11-30 | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
US17/479,990 Pending US20210401916A1 (en) | 2016-12-30 | 2021-09-20 | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/474,528 Active US11160840B2 (en) | 2016-12-30 | 2017-11-30 | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Country Status (5)
Country | Link |
---|---|
US (2) | US11160840B2 (en) |
KR (2) | KR102046763B1 (en) |
CN (1) | CN110740648A (en) |
AU (2) | AU2017385661B2 (en) |
WO (1) | WO2018124508A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11628195B2 (en) | 2019-06-03 | 2023-04-18 | Cosmax Nbt, Inc. | Method for preparing iridoid-rich noni fruit extract or fraction thereof, method for preparing immune-enhancing active material-rich noni fruit extract or fraction thereof and use of noni fruit extract or fraction thereof |
US11980649B2 (en) | 2020-02-19 | 2024-05-14 | Cosmax Nbt, Inc. | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising Agastache rugosa and licorice extract |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102046763B1 (en) * | 2016-12-30 | 2019-11-20 | 연세대학교 산학협력단 | Composition comprising 3,5-dicaffeoylquinic acid or extract of chrysanthemum as an effective ingredient for preventing or treating of muscular disorder or improvement of muscular functions |
CA3078234A1 (en) | 2017-10-06 | 2019-04-11 | Cargill, Incorporated | Readily dissolvable steviol glycoside compositions |
KR20200050068A (en) * | 2018-10-31 | 2020-05-11 | 고려대학교 산학협력단 | Composition Comprising the 3,5-Dicaffeoylquinic Acid for Recovery of Distrupted Skin Barrier and/or Alleviating Skin Inflammation |
KR102209142B1 (en) * | 2019-02-27 | 2021-01-28 | 마수정 | Chrysanthemum chocolate and the manufacturing method thereof |
AU2020273144A1 (en) | 2019-04-06 | 2021-11-04 | Cargill, Incorporated | Methods for making botanical extract composition |
CN113727614B (en) | 2019-04-06 | 2024-06-04 | 嘉吉公司 | Sensory modifier |
CN111548271A (en) * | 2020-04-20 | 2020-08-18 | 湖南鸿利药业股份有限公司 | Preparation method of honeysuckle isochlorogenic acid A |
CN116808092A (en) * | 2023-08-08 | 2023-09-29 | 成都中医药大学 | Application of chrysanthemum extract in preparing medicine for treating limb atrophy after ischemic stroke |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101368954B1 (en) * | 2011-06-23 | 2014-02-28 | 농업회사법인 맑은내일 주식회사 | Composition with stimulating effect, comprising the extract of medicinal plants |
US20190030200A1 (en) * | 2016-08-10 | 2019-01-31 | Jingning Wang | Air scavenger composition |
US11160840B2 (en) * | 2016-12-30 | 2021-11-02 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9662360B2 (en) * | 2008-10-09 | 2017-05-30 | Meritus Corporation | Treatment of herpes, pseudomonas, staph, and hepatitis |
JP5039305B2 (en) * | 2005-02-28 | 2012-10-03 | 花王株式会社 | Prophylactic anti-stress agent |
CN101185668A (en) * | 2006-11-15 | 2008-05-28 | 广州联创思远利生物科技有限公司 | Novel preparation for preventing and controlling acquired immuno-deficiency syndrome and protecting liver and detoxication |
FR2926955B1 (en) * | 2008-02-01 | 2012-07-20 | Agronomique Inst Nat Rech | PROCESS FOR THE PREPARATION OF DICAFEOYLQUINIC ACIDS AND THEIR USE IN THE FIGHT AGAINST PUCERONS |
JP2010195696A (en) * | 2009-02-24 | 2010-09-09 | Ichimaru Pharcos Co Ltd | PREPARATION FOR ACTIVATING Akt-mTOR-p70S6K OF MUSCLE STRENGTHENING SYSTEM AND METHOD THEREOF |
CN102355898B (en) * | 2009-03-18 | 2016-10-05 | 花王株式会社 | Agent for promoting energy consumption |
EP2324840B1 (en) * | 2009-11-18 | 2019-03-20 | Croda Italiana S.p.A. | Production of caffeoylquinic acids from plant cell cultures of echinacea angustifolia |
KR20110059513A (en) * | 2009-11-27 | 2011-06-02 | 웅진코웨이주식회사 | Compound comprising extracts or fractions of chrysanthemum boreale makino having anti-inflammation activity |
KR101253279B1 (en) * | 2011-01-10 | 2013-04-10 | 중앙대학교 산학협력단 | Anti-Bacterial Composition Comprising Extract from Leaf of Ilex rotunda or Phenylpropanoid Compound As Active Ingredient |
KR101385191B1 (en) * | 2012-06-25 | 2014-04-21 | 연세대학교 원주산학협력단 | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy |
CN102772466A (en) * | 2012-08-29 | 2012-11-14 | 苏州大学 | Application of chrysanthemum extract |
GB201317286D0 (en) * | 2013-09-30 | 2013-11-13 | Calscience Internat Ltd | Composition and Use |
CN104546819A (en) * | 2013-10-09 | 2015-04-29 | 中国医学科学院药物研究所 | Use of dicaffeoylquinic acid in treatment of systemic autoimmune disease |
JP6613515B2 (en) * | 2013-10-30 | 2019-12-04 | 株式会社東洋新薬 | Myoblast proliferation promoter and focus adjustment function improving agent |
CN104324282A (en) * | 2013-11-12 | 2015-02-04 | 魏钰 | Method for preparing medicament for treating muscular soreness |
US20150209399A1 (en) * | 2013-12-05 | 2015-07-30 | Applied Food Sciences, Inc. | Methods For Enhacement Of Dehydroepiandrosterone Using Green Coffee Bean Extract |
WO2016127399A1 (en) * | 2015-02-13 | 2016-08-18 | 四川九章生物科技有限公司 | Use of chlorogenic acid in preparing drug for treating amyotrophic lateral sclerosis |
CN105012908A (en) * | 2015-07-21 | 2015-11-04 | 王乾林 | Traditional Chinese medicine preparation for treating strain of lumbar muscles |
CN105395940A (en) * | 2015-12-09 | 2016-03-16 | 徐冉 | Chinese medicinal composition mainly treating hemifacial spasm and preparation method |
CN105878644A (en) * | 2016-05-05 | 2016-08-24 | 寇景波 | Medicinal liquor as well as preparation method and use thereof |
-
2017
- 2017-11-30 KR KR1020170162407A patent/KR102046763B1/en active IP Right Grant
- 2017-11-30 WO PCT/KR2017/013879 patent/WO2018124508A1/en active Application Filing
- 2017-11-30 US US16/474,528 patent/US11160840B2/en active Active
- 2017-11-30 AU AU2017385661A patent/AU2017385661B2/en active Active
- 2017-11-30 CN CN201780080862.1A patent/CN110740648A/en active Pending
-
2019
- 2019-07-29 KR KR1020190091854A patent/KR102047222B1/en active IP Right Grant
-
2020
- 2020-01-11 AU AU2020200225A patent/AU2020200225B2/en active Active
-
2021
- 2021-09-20 US US17/479,990 patent/US20210401916A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101368954B1 (en) * | 2011-06-23 | 2014-02-28 | 농업회사법인 맑은내일 주식회사 | Composition with stimulating effect, comprising the extract of medicinal plants |
US20190030200A1 (en) * | 2016-08-10 | 2019-01-31 | Jingning Wang | Air scavenger composition |
US11160840B2 (en) * | 2016-12-30 | 2021-11-02 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract |
Non-Patent Citations (4)
Title |
---|
Chae, S. An Up to Date Review of Phytochemicals and Biological Activities in Chrysanthemum spp. Biosciences and Biotechnology Research 13(2)615-623, June 2016. (Year: 2016) * |
Hodgson, A. et al. The Metabolic and Performance Effects of Caffeine Compared to Coffee During Endurance Exercise. PLoS One 8(4)1-9 April 2013. (Year: 2013) * |
Nakajima Y. et al. Water Extract of Propolis and its Main Constituents, Effects via Antioxidant Actions. Life Sciences 80(4)370-377, Jan 2007. (Year: 2007) * |
Park, K. et al. The Anti-Oxidative and Anti-Inflammatory Effects of Caffeoyl Derivatives from the Roots of Aconitum koreanum. Biological & Pharmaceutical Bulletin 32(12)2029-2033, 2009. (Year: 2009) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11628195B2 (en) | 2019-06-03 | 2023-04-18 | Cosmax Nbt, Inc. | Method for preparing iridoid-rich noni fruit extract or fraction thereof, method for preparing immune-enhancing active material-rich noni fruit extract or fraction thereof and use of noni fruit extract or fraction thereof |
US11980649B2 (en) | 2020-02-19 | 2024-05-14 | Cosmax Nbt, Inc. | Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising Agastache rugosa and licorice extract |
Also Published As
Publication number | Publication date |
---|---|
WO2018124508A1 (en) | 2018-07-05 |
KR102046763B1 (en) | 2019-11-20 |
AU2020200225B2 (en) | 2021-07-08 |
KR102047222B1 (en) | 2019-11-21 |
KR20180079174A (en) | 2018-07-10 |
US11160840B2 (en) | 2021-11-02 |
AU2017385661B2 (en) | 2020-03-05 |
CN110740648A (en) | 2020-01-31 |
AU2020200225A1 (en) | 2020-02-06 |
KR20190094322A (en) | 2019-08-13 |
US20200009208A1 (en) | 2020-01-09 |
AU2017385661A1 (en) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210401916A1 (en) | Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract | |
KR101767244B1 (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising balloon-flower extract | |
US10576057B2 (en) | Methods for treating muscle wasting and degeneration diseases | |
KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
EP3326638A1 (en) | Pharmaceutical composition for preventing or treating il-6-mediated diseases comprisingrosa rugosa | |
KR102124986B1 (en) | Composition for prevention or treatment of muscular disorder or improvement of muscular functions comprising Leonurus japonicus extract or leonurine | |
KR102349702B1 (en) | Skin whitening composition comprising crataegus pinnatifida extract or fractions thereof | |
KR101838379B1 (en) | Composition for increasing salivary secretion, or prevention, improvement or treatment of xerostomia of disorder of salivation comprising curcuma xanthorrhiza extract or xanthorrhizol | |
EP2842558A1 (en) | Cgrp responsiveness promoter | |
JP5925028B2 (en) | Skin lightening agent | |
KR101986883B1 (en) | Composition comprising Cymene or as active ingredients for Preventing or treating muscle disease | |
KR20200083146A (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Illicium verum extract or shikimic acid | |
KR102567263B1 (en) | Composition for preventing, treating or improving metabolic diseases containing essential oil mixture of Mentha haplocalyx, Citrus unshiu peel and Coicis Semen | |
KR102088569B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising essential oils extracted from Cnidii Rhizoma | |
KR101947907B1 (en) | Composition comprising eucalyptol or as active ingredients for muscle strengthening, development, differentiation, regeneration or inhibiting muscle atrophy | |
KR20200123688A (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Artemisia argyi extract | |
KR20240055203A (en) | Pharmaceutical composition for preventing or treating metabolic diseases comprising Tribulus terrestris extract | |
KR20240054647A (en) | Pharmaceutical composition for preventing or treating metabolic diseases comprising Rheum undulatum root extracts | |
KR20240054648A (en) | Pharmaceutical composition for preventing or treating metabolic diseases comprising Potentilla anserina extract | |
KR20230020056A (en) | The novel function of L-limonene as a selective glucocorticoid receptor agonist | |
KR20190000611A (en) | Composition comprising pulegone or as active ingredients for muscle strengthening, development, differentiation, regeneration or inhibiting muscle atrophy | |
KR20180081361A (en) | Composition comprising Indole-3-carbinol or as active ingredients for Preventing or treating muscle disease | |
KR20150112150A (en) | Composition for anticancer comprising methanol extract of Lysimachia foenum-graecum or its fraction as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |